Exhibit 10.1


 


Confidential Treatment – Asterisked material
has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.


 


OUT-LICENCE AGREEMENT


 


by and between


 


ASTRAZENECA AB


 


and


 


NEOPROBE CORPORATION


 


DATE: 9 DECEMBER 2011 


 



    	 	 	9 December 2011
AZ./.Neoprobe



    	 



    

 


TABLE OF CONTENTS


 


	1	Definitions	1
	 	 	 
	2	Construction	12
	 	 	 
	3	Grant of Rights	12
	3.1	Licence Grants to Neoprobe	12
	3.2	Option to Negotiate a Joint Commercial Arrangement	14
	3.3	Assignment of Regulatory Documentation	15
	3.4	Right of Reference	15
	3.5	Sublicences	16
	3.6	Exclusivity Term	17
	 	 	 
	4	Confirmatory Patent Licences	17
	 	 	 
	5	Development and Commercialisation	17
	5.1	Information Disclosure; Assistance	17
	5.2	Diligence Obligations	18
	5.3	Breach of Diligence Obligations	19
	5.4	AstraZeneca’s Retained Obligations	20
	5.5	Management of the Development Activities	20
	5.6	Records and Reporting	22
	5.7	Communications with Health Authorities	23
	 	 	 
	6	Consideration	23
	6.1	Milestone Payments	23
	6.2	Royalties	24
	6.3	Sublicensee Revenue	25
	6.4	Royalty Term	25
	6.5	Sales Subject to Royalties	25
	6.6	Royalty Payments	26
	6.7	Records Retention; Audit	26
	6.8	Mode of Payment	27
	6.9	Currency	27
	6.10	Taxes	27
	6.11	Interest on Late Payment	28


 



    	 	(i)	9 December 2011
AZ./.Neoprobe



    	 



    

 


	7	Supply to AstraZeneca	28
	 	 	 
	8	Ownership of Intellectual Property and Regulatory Documentation	29
	8.1	Ownership of Inventions	29
	8.2	Ownership of Licensed Patents and Licensed Know-How	29
	8.3	Ownership of Regulatory Documentation	29
	8.4	Ownership of Joint Patents and Joint Know-How	30
	 	 	 
	9	Adverse Event Reporting and Product Recall	30
	9.1	Adverse Event Reporting	30
	9.2	Notification and Recall	30
	 	 	 
	10	Confidentiality & Non-Disclosure	31
	10.1	Defined; General Obligations	31
	10.2	Permitted Disclosures	31
	10.3	Exclusions	32
	10.4	Use of Name	34
	10.5	Publications	34
	10.6	Equitable Relief	35
	 	 	 
	11	Trademarks and INN	35
	 	 	 
	12	Representations and Warranties	35
	12.1	Representations, Warranties and Covenants	35
	12.2	Additional Representations and Warranties of AstraZeneca	37
	12.3	DISCLAIMER OF WARRANTY	38
	 	 	 
	13	Indemnity	39
	13.1	Indemnification of AstraZeneca	39
	13.2	Indemnification of Neoprobe	39
	13.3	Notice of Claim	40
	13.4	Indemnification Procedures	40
	13.5	LIMITATION ON DAMAGES	42
	13.6	Insurance	43


 



    	 	(ii)	9 December 2011
AZ./.Neoprobe



    	 



    

 


	14	Maintenance and Prosecution of Patents	43
	14.1	Licensed Patents	43
	14.2	Cooperation	43
	14.3	AstraZeneca Election not to Prosecute	44
	14.4	Neoprobe Election not to Reimburse	44
	14.5	Joint Patents	45
	14.6	AstraZeneca Liability	45
	 	 	 
	15	Enforcement of Patents	46
	15.1	Rights and Procedures	46
	15.2	ANDA Certification	47
	15.3	Costs and Expenses	47
	 	 	 
	16	Potential Third Party Rights	47
	16.1	Third Party Licences	47
	16.2	Invalidity or Unenforceability Defences or Actions	48
	16.3	Third Party Litigation	49
	 	 	 
	17	Term and Termination	49
	17.1	Term	49
	17.2	Termination by Neoprobe	50
	17.3	Termination for Material Breach	50
	17.4	Termination by AstraZeneca	51
	17.5	Change of Control	51
	17.6	Consequences of Termination	52
	17.7	Accrued Rights; Surviving Obligations	54
	17.8	Termination Upon Insolvency	55
	17.9	Rights in Bankruptcy	55
	 	 	 
	18	Force Majeure	56
	 	 	 
	19	Assignment	57
	 	 	 
	20	Severability	57
	 	 	 
	21	Governing Law and Arbitration	57
	21.1	Governing Law	57
	21.2	Arbitration	58
	21.3	Attorneys’ Fees and Related Costs	58


 



    	 	(iii)	9 December 2011
AZ./.Neoprobe



    	 



    

 


	22	Notices	58
	22.1	Notice Requirements	58
	22.2	Address for Notice	59
	 	 	 
	23	Standstill	59
	 	 	 
	24	Relationship of the Parties	61
	 	 	 
	25	Entire Agreement	62
	 	 	 
	26	English Language	62
	 	 	 
	27	Amendment	62
	 	 	 
	28	Waiver and Non-Exclusion of Remedies	62
	 	 	 
	29	No Benefit to Third Parties	63
	 	 	 
	30	Further Assurance	63
	 	 	 
	31	Expenses	63
	 	 	 
	32	Counterparts	63


 



    	 	(iv)	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


LICENCE AGREEMENT


 


This Licence Agreement (the “Agreement”)
is made effective as of the 9th day of December 2011 (the “Effective Date”) by and
between:


 


		(1)	ASTRAZENECA AB, a Swedish corporation with offices at S-151 85 Södertälje, Sweden (“AstraZeneca”);
and



 


		(2)	Neoprobe Corporation, a Delaware USA corporation with offices at 425 Metro Place North, Suite 300, Dublin, OH 43017,
United States (“Neoprobe”)



 


Recitals


 


		(A)	WHEREAS, AstraZeneca has rights in respect of AZD4694 primarily intended for diagnostic use in the area of Alzheimer’s
Disease and other central nervous system disorders in humans;



 


		(B)	WHEREAS, Neoprobe itself and through sub-contractors has experience in, among other things, the development and commercialisation
of diagnostic and other pharmaceutical compounds; and



 


		(C)	WHEREAS, AstraZeneca desires to grant a licence to Neoprobe, and Neoprobe desires to take a licence, to develop and commercialise
the above-mentioned pharmaceutical compound in accordance with the terms and conditions set forth below.



 


NOW, THEREFORE, in consideration of the mutual covenants contained
in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
Parties, intending to be legally bound, agree as follows:


 


		1	Definitions



 


Unless otherwise specifically provided herein, the
following terms, when used with a capital letter at the beginning, shall have the following meanings:


 


		1.1	“Affiliate” means, with respect to a Person, any Person that directly, or indirectly through one or more
intermediaries, controls, is controlled by or is under common control with such first Person. “Control” and, with correlative
meanings, the terms “controlled by” and “under common control with” mean (a) the power to direct the management
or policies of a Person, whether through ownership of voting securities or by contract relating to voting rights or corporate governance,
resolution, regulation or otherwise, or (b) to own more than 50% of the outstanding voting securities or other ownership interest
of such Person.



 



    	 	Page 1 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		1.2	“Applicable Law” means the applicable laws, rules and regulations, including any rules, regulations, guidelines
or other requirements of the Health Authorities, that may be in effect from time to time in the Territory.



 


		1.3	“Additional Markets” means each of [*].



 


		1.4	“AstraZeneca Clinical Studies” means
the Phase II Clinical Trials regarding the Licensed Product in accordance with each Study Plan carried out by or on behalf of
AstraZeneca or its Affiliates as of the Effective Date.



 


		1.5	“Breaching Party” has the meaning set forth in Section 17.3.



 


		1.6	“Calendar Quarter” means each successive period of three (3) calendar months commencing on 1st January,
1st April, 1st July and 1st October.



 


		1.7	“Calendar Year” means each successive period of twelve (12) calendar months commencing on 1st January.



 


		1.8	“Change of Control,” with respect to any Person, means an event in which:



 


		1.8.1	any other Person or group of Persons acquires beneficial ownership of securities of such first Person representing more than
fifty percent (50%) of the voting power of the then outstanding securities of such first Person with respect to the election of
directors of such first Person; or



 


		1.8.2	such Person enters into a merger, consolidation or similar transaction with another Person in which such first Person is not
the surviving entity in such transaction.



 


		1.8.3	such Person enters into a merger, consolidation or similar transaction with another Person in which such Person is the surviving
entity in such transaction but (i) the members of the Board of Directors of such Person immediately prior to such transaction constitute
less than fifty percent (50%) of the members of the Board of Directors of such Person following such transaction or (ii) the Persons
who beneficially owned the outstanding voting securities of such Person immediately prior to such transaction cease to beneficially
own securities of such Person representing at least fifty percent (50%) of the voting power of the then outstanding securities
of such Person with respect to the election of directors immediately after such transaction in substantially the same proportions
as their ownership of securities of such Person immediately prior to such transaction; or



 



    	 	Page 2 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		1.8.4	such Person sells to any Person(s), in one or more related transactions, properties or assets (i) representing more than fifty
percent (50%) of such Person’s consolidated total assets or (ii) from which more than fifty percent (50%) of such Person’s
consolidated operating income for its most recent fiscal year was derived.



 


		1.9	“Commercially Reasonable Efforts” means, with respect to the research, development, Manufacture or commercialisation
of a Licensed Product, as the case may be, efforts and resources commonly used by prudent business persons in the research-based
pharmaceutical industry for products with similar commercial potential at a similar stage in their lifecycle. Commercially Reasonable
Efforts shall be determined on a market-by-market basis for each Licensed Product, without regard to any other product opportunities
of such Party. For purposes of this Agreement, Commercially Reasonable Efforts will not be deemed to require a Person to undertake
extraordinary or unreasonable measures, including the extraordinary or unreasonable expenditure of funds.



 


		1.10	“Complaining Party” has the meaning set forth in Section 17.3.



 


		1.11	“Compound” or “Compounds” means the compound AZD4694 described in Schedule 1 or any other
radioligand compound that binds to A-beta, covered by the Licensed Patents, including any intermediates, precursors, metabolites,
salts, esters, free acid forms, free base forms, pro-drug forms, racemates and all optically active forms of any such compound.



 


		1.12	“Confidential Information” has the meaning set forth in Section 10.1.



 


		1.13	“Control” means, with respect to any item of Information, Patent or Intellectual Property Right, possession
of the right, whether directly or indirectly, and whether by ownership, licence or otherwise, to assign, or grant a licence, sublicense
or other right to or under, such Information, Patent or Intellectual Property Right as provided for herein without violating the
terms of any agreement or other arrangement with any Third Party.



 



    	 	Page 3 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		1.14	“Data Exclusivity” means any data or market exclusivity periods, including any such periods listed in the
FDA’s Orange Book or periods under national implementations of Directive 2001/EC/83, and all international equivalents.



 


		1.15	“Development Activities” has the meaning defined in Section 5.5.1.



 


		1.16	“Development Plan” means the plan attached as a Schedule 2, outlining the Development Activities
and setting forth prioritisation criteria for specific components under the Development Activities, including proposed dates for
experimental initiation and completion of each stage of the Development Activities.



 


		1.17	“Direct Costs” means materials, labor and expenses related to the production
of a Compound or Licensed Product.



 


		1.18	“Disclosing Party” has the meaning set forth in Section 10.1.



 


		1.19	“Drug Master File” means the chemistry, manufacturing and control documentation for a Compound or Licensed
Product filed by AstraZeneca with a Health Authority.



 


		1.20	“Effective Date” has the meaning set forth in the preamble to this Agreement.



 


		1.21	“Europe” means the European Economic Area as it may be constituted from time to time.



 


		1.22	“Exploit” means to make, have made, import, use, sell, or offer for sale, including to research,
develop, register, modify, enhance, improve, Manufacture, have Manufactured, hold/keep (whether for disposal or otherwise), have
used, export, transport, distribute, promote, market or have sold or otherwise dispose or offer to dispose of, a product or process.



 


		1.23	“Exploitation” means the act of Exploiting a product or process.



 


		1.24	“Field” means the diagnosis, imaging or other assessment of central nervous system disorders.



 


		1.25	“First Commercial Sale” means the first sale for monetary value for use or consumption by the general public
of a Licensed Product in a country in the Territory.



 


		1.26	“Force Majeure” has the meaning set forth in Section 18.1.



 



    	 	Page 4 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		1.27	“Force Majeure Party” means a Party prevented or delayed in its performance under this Agreement by an event
of Force Majeure.



 


		1.28	“GAAP” means Generally Accepted Accounting Principles as in effect in the United States.



 


		1.29	“Government Official” means any Person employed by or acting on behalf of a government, government-controlled
entity or public international organization; any political party, party official or candidate; any Person who holds or performs
the duties of an appointment, office or position created by custom or convention; and any Person who holds himself out to be the
authorized intermediary of any of the foregoing.



 


		1.30	“Grant-Back Patents” means any Patents that, at the termination of this Agreement, Neoprobe or its Affiliates
own or otherwise Control and are necessary or reasonably useful for the Exploitation of the Licensed Products or Compounds or that
claim or cover Neoprobe’s Improvements to the Licensed Products or Compounds.



 


		1.31	“Health Authority” means any applicable supra-national, federal, national, regional, state, provincial or
local regulatory agencies, departments, bureaus, commissions, councils or other government entities regulating or otherwise exercising
authority with respect to the Exploitation of the Compounds or Licensed Products in the Territory.



 


		1.32	“Health Registration Approval” means, with respect to a country in the Territory, any and all approvals,
licences, registrations or authorisations of any Health Authority necessary to distribute, sell or market a Licensed Product in
such country, including, where applicable, (a) pricing or reimbursement approval in such country, (b) pre- and post-approval marketing
authorisations (including any prerequisite Manufacturing approval or authorisation related thereto), (c) labelling approval and
(d) technical, medical and scientific licences.



 


		1.33	“Improvements” means any invention, discovery, development or modification with respect to a Compound or
Licensed Product or relating to the Exploitation thereof, whether or not patented or patentable, that is conceived, reduced to
practice, discovered, developed or otherwise made at any time during the term of this Agreement, including any enhancement in the
efficiency, operation, Manufacture, ingredients, preparation, presentation, formulation, means of delivery or dosage of such Compound
or Licensed Product, any discovery or development of any new or expanded indications for such Compound or Licensed Product or any
discovery or development that improves the stability, safety or efficacy of such Compound or Licensed Product.



 



    	 	Page 5 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		1.34	“Indemnification Claim Notice” has the meaning set forth in Section 13.3.



 


		1.35	“Indemnified Party” means a Party seeking to recover a Loss under Section 13.1 or 13.2.



 


		1.36	“Indemnifying Party” means a Party from whom recovery of a Loss is sought under Section 13.1 or 13.2.



 


		1.37	“Indemnitee” has the meaning set forth in Section 13.3.



 


		1.38	“Indirect Costs” means costs related to the production of a Compound or Licensed
Product that are not directly accountable to the particular production function or product, and which may be fixed or variable,
including, but not limited to, taxes, administration, personnel and security costs.



 


		1.39	“Indirect Taxes” means value added taxes, sales taxes, consumption taxes and other similar taxes.



 


		1.40	“Information” means all technical, scientific and other know-how and information, trade secrets, knowledge,
technology, means, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical
assistance, designs, drawings, assembly procedures, computer programs, apparatuses, specifications, data, results and other material,
in written, electronic or any other form now known or hereafter developed, but excluding the Regulatory Documentation and the Drug
Master File.



 


		1.41	“Intellectual Property Rights” means trademarks, service marks, trade names, registered designs, design
rights, copyrights (including rights in computer software), database rights and any rights or property similar to any of the foregoing
(other than Patents) in any part of the world whether registered or not registered together with the right to apply for the registration
of any such rights.



 


		1.42	“Joint Know-How” has the meaning set forth in Section 8.4.



 


		1.43	“Joint Patents” has the meaning set forth in Section 8.4.



 



    	 	Page 6 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		1.44	“Joint Steering Committee” or “JSC” has the meaning set forth in Section 5.5.1.



 


		1.45	“Karolinska Agreement” means the Research Collaboration Agreement entered into by and between AstraZeneca
and Karolinska Institutet, Stockholm, Sweden, on 30 May 2006 regarding research collaboration on PET.



 


		1.46	“Knowledge” means the good faith understanding of the vice presidents, senior vice presidents, executive
vice presidents in the area of the Central Nervous System and Pain Innovative Medicines Unit within AstraZeneca of the facts and
information then in their possession without any duty to conduct any investigation with respect to such facts and information.



 


		1.47	“Licensed Know-How” means all Information that is Controlled by AstraZeneca or its Affiliates as of the
Effective Date set forth in Schedule 3 or that is otherwise necessary for the Exploitation of the Compounds or the Licensed Products,
that is not generally known, but excluding any Information to the extent covered or claimed by the Licensed Patents.



 


		1.48	“Licensed Patents” means (a) all patent applications and patents set forth in Schedule 4 hereto, and (b)
any Patents deriving from such patent applications.



 


		1.49	“Licensed Product” means products in forms suitable for human applications that contain a Compound as the
sole active ingredient.



 


		1.50	“Losses” means any and all liabilities, claims, demands, causes of action, damages, loss and expenses, including
interest, penalties, reasonable lawyers’ fees and disbursements, economic loss and loss of profit, future revenue and reputation
or goodwill, whether or not foreseeable. In calculating Losses, the legal duty to mitigate on the part of the Party suffering the
Losses shall be taken into account.



 


		1.51	“Major Market” means each of [*].



 


		1.52	“Manufacture” and “Manufacturing” means, with respect to a product or compound, the synthesis,
manufacturing, processing, formulating, packaging, labelling, holding, quality control testing and radiolabelling of such product
or compound.



 


		1.53	“Neoprobe Product Data” has the meaning set forth in Section 17.6.2(a).



 


		1.54	“Neoprobe Trademarks” means all Trademarks used by or on behalf of Neoprobe, its Affiliates or Sublicensees
prior to the termination of this Agreement in connection with the Compounds or Licensed Products and any registrations thereof,
or any pending applications relating thereto.



 



    	 	Page 7 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		1.55	“Net Sales” means (i) the gross amount invoiced on sales of a precursor of the Compound by Neoprobe or its
Affiliates to Third Parties or to its Sublicensees, and (ii), subject to Section 6.3, the gross amount invoiced on sales of the
Licensed Product by Neoprobe, its Affiliates or Sublicensees to Third Parties in each case after deduction of:



 


		1.55.1	normal and customary trade or quantity discounts (including chargebacks and allowances) actually allowed;



 


		1.55.2	amounts repaid or credited by reason of rejection, returns or recalls of goods, rebates;



 


		1.55.3	rebates and similar payments made with respect to sales paid for by any governmental or regulatory authority such as, by way
of illustration and not in limitation of the Parties’ rights hereunder, Federal or state Medicaid, Medicare or similar state
program in the United States or equivalent governmental program in any other country;



 


		1.55.4	transportation costs, distribution expenses, special packaging and related insurance charges to the extent that such items
are included in the gross amount invoiced;



 


		1.55.5	with respect to Neoprobe’s or its Affiliates’ sales directly to hospitals and other end users as contemplated under
(ii) above, compounding and pharmacy preparation charges not exceeding [*] of the gross amount invoiced on such sales of Licensed
Product, to the extent that such items are included in the gross amount invoiced; and



 


		1.55.6	excise taxes, Indirect Taxes and customs duty imposed on the sale, importation, use or distribution of the Licensed Products
(but not including taxes assessed against the income derived from such sale).



 


Any of the deductions listed above that involves
a payment by Neoprobe or its Affiliates or Sublicensees shall be taken as a deduction in the Calendar Quarter in which the payment
is incurred by such entity. For purposes of calculating the Net Sales of bundled products, deductions shall be apportioned across
all products in the bundle on a fair and reasonable basis, provided that the percentage rebate or discount apportioned to the Licensed
Product shall not exceed the percentage rebate or discount applied in total to the bundled products. Similarly the total price
payable for a bundled product shall be apportioned between Licensed Product and other product within the bundle on a fair and reasonable
basis.


 



    	 	Page 8 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


By way of example and without limiting the generality
of what is stated in the first paragraph of this Section 1.55, sales by Neoprobe of precursors to a radiopharmacy (which is a Sublicensee)
would trigger the calculation under (i), and the radio pharmacy’s sales of the Licensed Product to Third Parties would trigger
an additional amount under (ii), if any, in accordance with what is stated in Section 6.3. Should Neoprobe have appointed a Sublicensee
that would do the sales of the precursor to a radiopharmacy then the sales by Neoprobe to such first Sublicensee would be part
of the Net Sales under (i) and the ultimate Sublicensee’s sales to a Third Party would generate an additional amount under
(ii), if any.


 


		1.56	“Notice Period” has the meaning set forth in Section 17.3.



 


		1.57	“Party” means either AstraZeneca or Neoprobe and “Parties” means both AstraZeneca and
Neoprobe.



 


		1.58	“Patents” means (a) all national, regional and international patents and patent applications, including
provisional patent applications, (b) all patent applications filed either from such patents, patent applications or provisional
applications or from an application claiming priority from either of these, including divisionals, continuations, continuations-in-part,
provisionals, converted provisionals, and continued prosecution applications, (c) any and all patents that have issued or in the
future issue from the foregoing patent applications ((a) and (b)), including utility models, petty patents and design patents and
certificates of invention, (d) any and all extensions or restorations by existing or future extension or restoration mechanisms,
including revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates and the
like) of the foregoing patents or patent applications ((a), (b) and (c)), (e) any similar rights, including so-called pipeline
protection, or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions
to any such foregoing patent applications and patents.



 


		1.59	“Payments” has the meaning set forth in Section 6.10.1.



 



    	 	Page 9 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		1.60	“Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership,
corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or
other similar entity or organisation, including a government or political subdivision, department or agency of a government.



 


		1.61	“Phase II Clinical Trial” means a human clinical trial to be conducted in a number of patients estimated
to be sufficient to initially test efficacy of the Licensed Product as a commercial imaging agent at a standard suitable to enable
Phase III Clinical Trials to be commenced with the Licensed product.



 


		1.62	“Phase III Clinical Trial” means a large scale, pivotal, multi-centre, human clinical trial to be conducted
in a number of patients estimated to be sufficient to establish efficacy of the Licensed Product as a commercial imaging agent
at a standard suitable to obtain a Health Registration Approval to market and sell such Licensed Product in a Major Market (excluding
dose ranging studies). A Phase III Clinical Trial shall be deemed to have commenced on the date the first patient is enrolled in
such Phase III Clinical Trial.



 


		1.63.	“Promote,” with correlative meanings, means any activity to market, promote or communicate the sale, supply
or use of the Licensed Product, including advertising, discussing the Licensed Product with doctors, patients and other potential
customers, making announcements, arranging and attending medical/scientific meetings and invitations or sponsorship to attend medical/scientific
meetings and public relations activities, and any other activities normally undertaken by a pharmaceutical company’s sales
force to implement marketing plans and strategies aimed at encouraging the appropriate use of a particular prescription or other
pharmaceutical product.



 


		1.64	“Regulatory Documentation” means all applications, registrations, licences, authorisations and approvals
(including all Health Registration Approvals), all correspondence submitted to or received from Health Authorities (including minutes
and official contact reports relating to any communications with any Health Authority) and all supporting documents and all clinical
studies and tests, relating to any Compounds or Licensed Products, and all data contained in any of the foregoing, including all
investigational new drug applications, Health Registration Approvals, regulatory drug lists, advertising and promotion documents,
adverse event files and complaint files.



 



    	 	Page 10 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		1.65	“Study Plan” means each clinical study
plan set forth in Schedule 5



 


		1.66	“Sublicensee” has the meaning set out in Section 3.5.



 


		1.67	“Territory” means all countries in the world, except for those countries in which this Agreement is terminated.



 


		1.68	“Third Party” means any Person not including the Parties, the Parties’ respective Affiliates or Sublicensees.



 


		1.69	“Third Party Claim” has the meaning set forth in Section 13.1.



 


		1.70	“Trademark” means any word, name, symbol, colour, designation or device or any combination thereof, including
any trademark, trade dress, brand mark, trade name, brand name, logo or business symbol used by Neoprobe in connection with the
Compounds or Licensed Products.



 


		1.71	“United States” or “U.S.” means the United States of America, including its territories
and possessions, the District of Columbia and Puerto Rico.



 


		1.72	“Valid Claim” means, with respect to a particular country, either:



 


		1.72.1	any claim of a granted and unexpired Patent in such country that (i) has not been held permanently revoked, unenforceable or
invalid by a decision of a court or other governmental agency of competent jurisdiction, which decision is unappealable or unappealed
within the time allowed for appeal, and (ii) has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable
through reissue or disclaimer or otherwise; or



 


		1.72.2	a claim of a pending Patent application, which claim was filed and is being prosecuted in good faith and has not been cancelled,
withdrawn, abandoned or finally disallowed without the possibility of appeal, re-filing of the application or filing of a divisional
or continuation application.



 



    	 	Page 11 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		2	Construction



 


Except where the context requires
otherwise, whenever used the singular includes the plural, the plural includes the singular, the use of any gender is applicable
to all genders and the word “or” has the inclusive meaning represented by the phrase “and/or”. Whenever
this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The headings of this
Agreement are for convenience of reference only and do not define, describe, extend or limit the scope or intent of this Agreement
or the scope or intent of any provision contained in this Agreement. The term “including” or “includes”
as used in this Agreement means including, without limiting the generality of any description preceding such term. All financial
and accounting calculations hereunder shall be determined according to GAAP, to the extent applicable. The wording of this Agreement
shall be deemed to be the wording mutually chosen by the Parties and no rule of strict construction shall be applied against any
Party.


 


		3	Grant of Rights



 


		3.1	Licence Grants to Neoprobe. Subject to the terms and conditions of this Agreement, AstraZeneca hereby grants to Neoprobe:



 


		3.1.1	an exclusive (subject AstraZeneca’s retained rights as set forth in Section 3.1.2 and subject to the non-exclusive licence
granted to Karolinska Institutet under the Karolinska Agreement) royalty-bearing licence in the Territory, with the right to grant
sublicenses pursuant to Section 3.5, under AstraZeneca’s rights, titles, and interests in and to the Licensed Patents,
the Licensed Know-How, the Joint Patents and the Joint Know-How to Exploit the Compounds and the Licensed Products and any Improvements
thereto in the Field.



 


		3.1.2	Notwithstanding what is stated in Section 3.1.1, AstraZeneca shall have a retained right



 


		(i)	under any licence or right granted under Section 3.1.1 for the purpose of AstraZeneca’s fulfilment of the activities
set forth in Section 5.4;



 



    	 	Page 12 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		(ii)	to Promote the Licensed Product in accordance with its most recent prescribing information as a biomarker whenever AstraZeneca
Promotes any pharmaceutical product Controlled by AstraZeneca, including, without limiting, displaying the intended use and benefit
of the Licensed Product for the proper administration, dosing or other application of such pharmaceutical product Controlled by
AstraZeneca; provided, however, that prior to commencing any such Promotion AstraZeneca shall notify the JSC in writing about such
planned activities and the intended message in reasonable detail to allow the JSC to assess whether such promotional message would
significantly impact in a negative way the promotional message regarding the Licensed Product. The JSC shall be allowed a reasonable
period of time but no more than three (3) weeks from such AstraZeneca’s notice to make such assessment and may within
such period raise by giving notice in writing to AstraZeneca any concerns it may have in these regards over such plans. Should
the JSC give such notice then AstraZeneca shall aim to respond within fourteen (14) days of receipt of such notice to the JSC how
AstraZeneca intends to address such concerns in its Promotion and shall take the comments provided by the JSC in such notice into
reasonable account when planning or conducting such activities; provided, however, that AstraZeneca shall have the ultimate right
to decide, at its discretion, how to structure such promotional message or other information as long as it is consistent with the
prescribing information in the country concerned, but further provided that such activities do not unreasonably conflict or interfere
with Neoprobe’s rights and obligations under this Agreement; and



 



    	 	Page 13 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		(iii)	to make, have made, import, use, including to research, develop, register, modify, enhance, improve, Manufacture, have Manufactured,
hold/keep, have used, export, transport, distribute (but, for the avoidance of doubt not sell, distribute, market or promote) the
Compound and the Licensed Product in the Field for use solely as a biomarker for the purpose of development of pharmaceutical products;
provided, however, that prior to any such use by AstraZeneca of the Compound or the Licensed Product AstraZeneca shall notify the
JSC in writing about such planned use describing the planned studies or other use in reasonable detail to allow the JSC to assess
whether the safety profile of the Licensed Product would be negatively impacted by the intended use by AstraZeneca. The JSC shall
be allowed a reasonable period of time but no more than three (3) weeks from such AstraZeneca’s notice to make such assessment
and may within such period raise by giving notice in writing to AstraZeneca any concerns it may have in these regards over such
plans. Should the JSC give such notice then AstraZeneca shall aim to respond within fourteen (14) days thereof to the JSC how AstraZeneca
intends to address such concerns in its planned use of the Compound or Licensed Product and shall take the comments provided by
the JSC in such notice into reasonable account when planning or conducting such studies or other activities; provided, however,
that AstraZeneca shall have the ultimate right to decide, at its discretion, how such studies or other activities are to be carried
out, but further provided that such studies or activities do not unreasonably conflict or interfere with Neoprobe’s rights
and obligations under this Agreement.



 


		3.2	Option to Negotiate a Joint Commercial Arrangement. AstraZeneca may at any time propose to Neoprobe that the parties
enter into a co-promotion agreement or other agreement regarding joint commercialisation (a “Joint Commercial Arrangement”)
of the Licensed Product and a pharmaceutical product Controlled by AstraZeneca for which the Licensed Product may be useful as
a companion diagnostic by giving Neoprobe notice hereof in writing outlining the commercial proposal in reasonable detail. Within
thirty (30) days of such notice the Parties shall enter into good faith negotiations to endeavour to establish mutually acceptable
terms for such Joint Commercial Arrangement including the establishment of a Joint Commercial Committee overseeing and governing
such activities; provided, however, that, subject to each Party using its reasonable endeavours to negotiate such arrangement,
neither Party shall be obligated to enter into such Commercial Arrangement or to amend this Agreement because of such option as
described in this Section 3.2.



 



    	 	Page 14 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		3.3	Assignment of Regulatory Documentation. AstraZeneca hereby assigns to Neoprobe all of its rights, titles and interests
in and to all Regulatory Documentation, including, to the extent permitted by Applicable Law, all Health Registration Approvals,
Controlled by AstraZeneca as of the Effective Date. Neoprobe shall be
responsible for the payment of any fee payable by the transferee on the transfer of such Regulatory Documentation.



 


AstraZeneca further hereby agrees to provide
during the first five (5) years after the Effective Date reasonable and necessary assistance to Neoprobe during the filing
and review of applications submitted by Neoprobe or its Affiliates for Health Registration Approvals and further maintenance of
such Health Registration Approvals during the term of this Agreement. It is acknowledged by Neoprobe that such assistance will
be utilised only to an extent absolutely required for the purpose of obtaining Health Registration Approval and in view of this
the Parties have agreed that AstraZeneca will not charge Neoprobe for such assistance. It is also recognised that the level of
assistance is likely going to gradually decrease over the five years period mentioned


 


		3.4	Right of Reference. Neoprobe shall permit AstraZeneca to cross-refer to any Regulatory Documentation assigned under
Section 3.3, at no additional cost to AstraZeneca, for the purposes of Exploiting the Licensed Products outside the Field and for
use under AstraZeneca’s retained rights as set forth in Section 3.1.2. Neoprobe hereby agrees to provide AstraZeneca with
a letter of consent to permit such cross-referencing, which letter may be provided by AstraZeneca to Health Authorities for purposes
of performing its obligations and exercising its retained rights hereunder. Neoprobe shall submit to appropriate Health Authorities
on a timely basis and maintain a Drug Master File or a similar dossier which may reasonably be required by such appropriate Health
Authorities. Neoprobe shall make available to AstraZeneca the Drug Master File, if applicable, or any other relevant supporting
documentation, on a timely basis as so requested by AstraZeneca, for each country of the Territory and at such times and in accordance
with a mutually agreed schedule as requested by AstraZeneca.



 


Neoprobe acknowledges that (a) the Licensed Know-How
is secret and substantial and that without Licensed Know-How Neoprobe would not be able to obtain and maintain Health Registration
Approvals, (b) such Health Registration Approvals together with the Health Registration Approvals assigned or licensed to Neoprobe
hereunder give, or will allow Neoprobe to obtain and maintain, Data Exclusivity with respect to the Compounds and Licensed Products,
(c) access to the Licensed Know-How and such Health Registration Approvals have provided Neoprobe with a competitive advantage
in the marketplace beyond the exclusivity afforded by the Licensed Patents and the Data Exclusivity, and (d) the milestone payments
and royalties set forth in Sections 6.1 and 6.2 are, in part, intended to compensate AstraZeneca for such exclusivity and
such competitive advantage.


 



    	 	Page 15 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		3.5	Sublicenses. Neoprobe shall have the right to grant sublicenses under the licences granted in Section 3.1.1, to
its Affiliates and to any other Persons in the Territory or in any country of the Territory;
provided, however, that:



 


(i)           
(a) Neoprobe shall procure the performance by any sublicensee of the terms of each such sublicense; (b) notwithstanding any such
sublicense, Neoprobe shall remain solely liable for the performance of its obligations hereunder; and (c) Neoprobe shall
prior to the execution of each such sublicense notify AstraZeneca in writing of such proposed sublicense and the terms thereof
and supply to AstraZeneca a copy of such sublicense and AstraZeneca shall provide Neoprobe in writing, within thirty (30) days,
its concerns or comments, if any, about such proposed sub-licence or sub-licensee, which concerns or comments shall be taken into
reasonable account by Neoprobe; and


 


(ii)           Neoprobe
may not grant a Third Party or a Sublicensee any sublicense under the licences granted or any other rights obtained from AstraZeneca
hereunder on an exclusive basis for the Exploitation of the Compound or the Licensed Product through co-promotion, co-marketing
or other commercial arrangement together with any compound or product Controlled by a Third Party or a Sub-licensee, whether or
not such Third Party’s or Sublicensee’s compound or product is used primarily for diagnostic purposes.


 



    	 	Page 16 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


Where Neoprobe grants a sublicense
to a Person that is not an Affiliate of Neoprobe, such Person shall be a “Sublicensee” for purposes of this
Agreement. “Sublicensees” shall also include any Person to which such Sublicensee grants a sublicence. Any Person that
Neoprobe or its Affiliates appoint or grant any right, to market, promote, sell, distribute or otherwise Exploit Compounds or Licensed
Products in any country in the Territory, and any Person that has been appointed or granted any such right by such Person, shall
be deemed to be a Sublicensee for purposes of this Agreement. For further certainty and without limiting the generality of the
foregoing, the Parties recognise that radiopharmacies to which Neoprobe, its Affiliates or any of its other Sublicensees supplies
a precursor of the Compound and grants a licence to the Licensed Product are Sublicensees. Neoprobe shall ensure that all
Persons to which it grants sublicenses, and other Persons deemed Sublicensees in accordance with the above, will comply with all
terms and conditions of this Agreement.


 


		3.6	Exclusivity Term. Neoprobe’s exclusive position granted by Section 3.1 shall expire with respect to each
separate Licensed Product, on a country-by-country basis, on the date when Neoprobe’s obligation to pay royalties with respect
to such Licensed Product pursuant to Section 6.4 expires. Upon expiry of Neoprobe’s exclusive position with respect
to a Licensed Product in a country, Neoprobe’s licence with respect to such Licensed Product in such country shall become
non-exclusive, fully paid-up, perpetual and irrevocable. Neoprobe and its Affiliates and Sublicensees shall be allowed to continue
Exploiting such Licensed Product and using all Licensed Know-How and Joint Know-How in connection therewith on a non-exclusive
basis in such country with no further consideration to AstraZeneca.



 


		4	Confirmatory Patent Licences



 


AstraZeneca shall if requested to do so by Neoprobe
promptly enter into confirmatory licence agreements in the form or substantially the form set out in Exhibit 1 for purposes of
recording the licences granted under this Agreement with such Patent Offices in the Territory as Neoprobe reasonably considers
appropriate. Until the execution of any such confirmatory licences, so far as may be legally possible, Neoprobe and AstraZeneca
shall have the same rights in respect of the Licensed Patents and be under the same obligations to each other in all respects as
if the said confirmatory licences had been executed.


 


		5	Development and Commercialisation



 


		5.1	Information Disclosure; Assistance.



 


		5.1.1	AstraZeneca shall, and shall cause its Affiliates to, disclose and make available to Neoprobe, in whatever form Neoprobe may
reasonably request, Regulatory Documentation, Licensed Know-How and any other Information claimed or covered by any Licensed Patent
or otherwise relating, directly or indirectly, to any Compound or Licensed Product, in each case that is in existence as of the
Effective Date, promptly after the Effective Date to the extent not done so already.



 



    	 	Page 17 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		5.1.2	AstraZeneca shall provide Neoprobe with reasonable assistance required in order to transfer the Licensed Know-How to Neoprobe
in a timely manner. Without prejudice to the generality of the foregoing, if visits of AstraZeneca’s representatives to Neoprobe’s
facilities are reasonably requested by Neoprobe for purposes of transferring the Licensed KnowHow to Neoprobe or for purposes of
Neoprobe acquiring expertise on the practical application of the Licensed Know-How or assisting on issues arising during such Exploitation,
AstraZeneca shall send appropriate representatives to Neoprobe’s facilities, provided that Neoprobe shall reimburse AstraZeneca
for its travel expenses, including transportation, lodging, meals and other similar expenses, for such representatives. It is acknowledged
by Neoprobe that such assistance will be utilised only to an extent absolutely required for the purposes stated above in this Section
5.1.2 and in view of this the Parties have agreed that AstraZeneca will not charge Neoprobe for such assistance. It is also recognised
that the level of assistance is likely going to gradually decrease over time and that as a general rule is not expected to be required
beyond the first twelve (12 months of the Effective Date.



 


		5.2	Diligence Obligations.



 


		5.2.1	Neoprobe undertakes to use Commercially Reasonable Efforts at its own cost to develop, Manufacture and commercialise a Licensed
Product for use in the Field in each Major Market in accordance with the terms and conditions of this Agreement, including Section 5.2.2,
including obtaining Health Registration Approval(s) to Manufacture, market and sell the Licensed Product for use in the Field in
each Major Market, and thereafter diligently marketing and selling the Licensed Product in each Major Market so as to maximize
sales.



 


		5.2.2	Without limiting any of the foregoing, Neoprobe shall use its Commercially Reasonable Efforts to achieve the following development
and commercialisation milestones, in each case, within the time period set forth below with respect to such obligation:



 



    	 	Page 18 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		(a)	Neoprobe shall [*]



 


		(b)	Neoprobe shall [*].



 


		5.2.3	Neoprobe shall perform, or cause to be performed, any and all of its development and commercialisation obligations as set forth
in this Agreement, including those obligations identified Section 5.2.1 and Section 5.2.2, in good scientific manner,
and in compliance in all material respects with all Applicable Law.



 


		5.2.4	Non-Compete. For a period of three (3) years after the Effective Date or, if this Agreement is terminated by either
Party prior to the expiration of such three-years period, for a period ending at the earlier of (i) the effective date of such
termination and (ii) the expiration of such three years period, each Party covenants that it and its Affiliates shall not, beyond
what is permitted under this Agreement, (a) conduct any activity with, for the benefit of, or sponsored by, any Person, that has
as its goal, intent or consequence of discovering, identifying, Exploiting or otherwise commercialising [*] or (b) grant any licence
or other rights to any Person to utilise any intellectual property Controlled by such Party or its Affiliates for the express purpose
of discovering, identifying, Exploiting or otherwise commercialising amyloid imaging agents.



 


		5.3	Breach of Diligence Obligations.



 


		5.3.1	Notification and Meeting. If at any time AstraZeneca has a reasonable basis to believe that Neoprobe is in breach of
its obligations under Section 5.2 with respect to a Major Market, then AstraZeneca shall so notify Neoprobe, specifying the
basis for its belief, and the Parties shall meet within thirty (30) days after such notice to discuss in good faith AstraZeneca’s
concerns and Neoprobe’s development and commercialisation plans with respect to the Licensed Product.



 



    	 	Page 19 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		5.3.2	Right of Termination. If after good faith discussions pursuant to Section 5.3.1, Neoprobe does not take reasonable
steps designed to rectify its breach of its obligations under Section 5.2 in such Major Market within sixty (60) days of meeting
with AstraZeneca pursuant to Section 5.3.1 or, if such failure cannot be rectified within such sixty (60)-day period, if Neoprobe
does not commence actions to rectify such failure within such period and thereafter diligently pursue such actions, AstraZeneca
may exercise its right of termination provided under Section 17.3.



 


		5.4	AstraZeneca’s Retained Obligations.  AstraZeneca undertakes to use Commercially Reasonable Efforts to continue
and complete at its cost the AstraZeneca Clinical Studies, in each case until issuance of the final report from the study concerned.
Such studies shall be conducted in accordance with the Study Plan for each study and in good scientific manner, and in compliance
in all material respects with all Applicable Laws.



 


		5.5	Management of the Development Activities



 


		5.5.1	Responsibilities of JSC. The Parties shall establish a Joint Steering Committee (the “JSC”) to oversee
the conduct of the development activities set forth in the Development Plan and otherwise under this Agreement (“Development
Activities”), act in an advisory capacity to the Parties as required by either of them following completion of the Development
Activities and address matters as may be brought to it by AstraZeneca in accordance with Section 3.1.2 (ii) or (iii). In particular,
the responsibilities of the JSC shall include monitoring timely execution of the Development Plan including compliance with timelines
and reviewing and approving any amendments to Development Plan.



 


In governing and overseeing
the Development Activities the JSC will take into account AstraZeneca’s interest being able to develop and utilise the Licensed
Product as a biomarker for its development of pharmaceutical products in accordance with its retained rights under Section 3.1.2.
In particular it is recognised that for regulatory reasons AstraZeneca may need to carry out studies and other development regarding
the Licensed Product in which studies or other activities Neoprobe sees no, or only limited, commercial potential, and the JSC
will reasonably accommodate such AstraZeneca needs with the objective of allowing AstraZeneca to utilise its retained rights in
an optimal way, provided that such use does not unreasonably conflict or interfere with Neoprobe’s rights and obligations
under this Agreement, or impose additional cost or expense on Neoprobe unless AstraZeneca declares itself willing to cover any
such additional cost or expense.


 



    	 	Page 20 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		5.5.2	Formation of JSC. The JSC shall consist of eight (8) members with the requisite experience and seniority to enable them
to make decisions on behalf of the Parties with respect to the Program, with equal numbers appointed by each Party, which shall
include a Co-Chair to be designated by each Party. Each Party shall have the right to replace its respective JSC representatives
upon written notice to the other Party, provided that any such substitute representative shall have substantially the equivalent
experience and seniority as the representative that such person replaces. Each Party shall cause its appointed members of the JSC
to act reasonably, in good faith, and consistently with the terms and spirit of this Agreement.



 


		5.5.3	Disputes. The JSC shall endeavour to reach consensus on all matters brought before it with each Party having a single
vote, irrespective of the number of representatives actually in attendance at a meeting; provided, however, that in the event the
JSC is unable to resolve an outstanding matter before it, such matter shall be resolved in good faith by the Vice President, Central
Nervous System & Pain Innovative Medicines Unit, of AstraZeneca and the Chief Executive Officer of Neoprobe. Any final
decision mutually agreed to by the said senior managements of the Parties shall be in writing and shall be conclusive and binding
on the Parties. If such resolution is unattainable by such representatives within thirty (30) days from
the date the matter in dispute is first brought to the attention of them, the dispute shall be resolved in accordance with Neoprobe’s
position. For the avoidance of doubt, whether or not the JSC decides in accordance with Neoprobe’s
position on a matter brought to the JSC by AstraZeneca under Section 3.1.2 (ii) or (iii), such decision shall not contravene or
conflict with any right expressly given to AstraZeneca under Section 3.1.2 (ii) or (iii).



 



    	 	Page 21 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		5.5.4	Meetings. The JSC shall meet at least every six months and more frequently when required. The meetings will be held
at the Parties’ offices in Södertälje, Sweden, and Dublin, Ohio every second time or by teleconference or videoconference.
A quorum of the JSC shall exist whenever there is present at a meeting each of the Co-Chairs or their respective designees. In
addition, the JSC may act without a formal meeting by a written memorandum signed by the Co-Chairs of the JSC. Whenever any action
by the JSC is required hereunder during a time period in which the JSC is not scheduled to meet, either Co-Chair shall have the
right to call a special meeting or the Co-Chairs may cause the JSC to take the action without a meeting in the applicable time
period. Any such additional meetings shall be held at places and on dates selected by the Co-Chairs.



 


		5.5.5	Expenses. Neoprobe and AstraZeneca each shall bear all expenses of its JSC members related to such members’ participation
on the JSC and attendance at JSC meetings.



 


		5.5.6	Minutes. The JSC shall keep accurate minutes of its deliberations, which minutes shall record all proposed decisions
and all actions recommended or taken.



 


		5.6	Records and Reporting. Neoprobe shall prepare and maintain complete and accurate records regarding the development and
commercialisation of the Licensed Products. AstraZeneca shall have the right from time to time, but not more frequently
than semi-annually, and upon reasonable prior written notice to Neoprobe to examine, during normal business hours, Neoprobe’s
records regarding such development and commercialisation activities. Neoprobe shall provide AstraZeneca with a quarterly report
on the progress in the development and commercialisation of Licensed Products (including a regulatory plan) in the Territory in
order to keep AstraZeneca informed of its progress. Such report shall cover, in relation to Compounds and Licensed Products, general
information on Neoprobe’s Development Activities in the previous Calendar Quarter, a summary of the activities planned in
the next Calendar Quarter, a timetable of planned and actual submissions for Health Registration Approvals, commercialisation plans,
activities and strategy and events otherwise being of importance for the Development Activities or the commercialisation of the
Licensed Product. Neoprobe shall provide AstraZeneca with such additional information regarding the development and commercialisation
of the Licensed Products as AstraZeneca may reasonably request. If and when a Health Registration Approval is obtained in
any country of the Territory, Neoprobe shall promptly inform AstraZeneca of such Health Registration Approval.



 



    	 	Page 22 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		5.7	Communications with Health Authorities. Neoprobe shall have the sole right and obligation to conduct all communications
with the Health Authorities with regard to the Compounds and Licensed Products in the Territory; provided, however,
that Neoprobe shall (a) notify AstraZeneca as early as reasonably practicable in advance of all meetings and significant communications
with the Health Authorities concerning the Compounds or Licensed Products, (b) permit representatives of AstraZeneca to attend
such meetings as an observer, and (c) forward to AstraZeneca copies of written correspondence to and from the Health Authorities,
promptly upon submission thereto or receipt therefrom, as applicable. AstraZeneca shall have no right to participate in discussions
at any such meeting it may attend or in any correspondence or other communications with such Health Authorities.



 


		6	Consideration



 


		6.1	Milestone Payments. In partial consideration of the licences and other rights granted by AstraZeneca to Neoprobe herein
and subject to the terms and conditions of this Agreement, Neoprobe shall pay AstraZeneca a sum of Twenty-Two Million Five Hundred
Thousand U.S. Dollars ($22,500,000) according to the following schedule:



 


		6.1.1	a non-refundable payment of Five Million U.S. Dollars ($5,000,000) within ten (10) days following the Effective Date;



 


		6.1.2	[*];



 


		6.1.3	[*];



 


		6.1.4	[*];



 


		6.1.5	[*];



 


		6.1.6	[*];



 


		6.1.7	[*];



 


		6.1.8	[*];



 


		6.1.9	[*];



 


		6.1.10	[*]; and



 


		6.1.11	[*].



 



    	 	Page 23 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


No payment in this Section 6.1 will be made
more than once irrespective of the number of Licensed Products that have achieved the milestone events set forth in this Section 6.1,
or the number of countries in which such milestone events have been achieved. Neoprobe
shall notify AstraZeneca promptly of any determination, filing or approval that would trigger a payment by Neoprobe to AstraZeneca
under this Section 6.1 and the amount of the
payment required. In addition, Neoprobe shall notify AstraZeneca promptly of any action, event or correspondence received from
any Health Authority that could suggest a delay in the achievement of any of the foregoing milestones.


 


		6.2	Royalties.



 


		6.2.1	In addition to the foregoing payments, Neoprobe shall pay AstraZeneca the following royalties on the Net Sales in the Territory
during each Calendar Year:



 


		(i)	On any portion of the aggregate Net Sales during such Calendar Year of less than [*] Neoprobe shall pay a royalty of [*] of
the aggregate Net Sales in the United States and [*] of the aggregate Net Sales in any other country in the Territory.



 


		(ii)	On any portion of the aggregate Net Sales during such Calendar Year that equals or exceeds [*] Neoprobe shall pay a royalty
of [*] of the aggregate Net Sales of in the United States and [*] of the aggregate Net Sales in any other country in the Territory.



 


		6.2.2	Notwithstanding what is stated in Section 6.2.1, commencing in the Calendar Month following the first commercial sale by AstraZeneca,
its Affiliates or licensees of a disease-modifying therapeutic product for the treatment of Alzheimer’s disease Neoprobe
shall in recognition of the expected expansion of the market in which the Licensed Product is sold pay to AstraZeneca instead of
the royalties set forth in Section 6.2.1 the following royalties on the Net Sales of the Licensed Products in the Territory during
each Calendar Year:



 


		(i)	[*] of the aggregate Net Sales in the United States; and



 


		(ii)	[*] of the aggregate Net Sales in any other country in the Territory.



 



    	 	Page 24 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		6.3	Sublicensee Revenue.



 


With respect to Net Sales
of Licensed Product by Sublicensees to Third Parties, royalties to AstraZeneca hereunder with respect to such Net Sales, for any
period, shall include any additional amount of royalties that would result from the royalty calculations under Section 6.2,
if such Net Sales were treated as Net Sales by Neoprobe for purposes of such calculation during such period, and there shall be
excluded from such calculation the amount paid to Neoprobe to acquire the precursor of the Compound (if such amount is included
in Net Sales pursuant to clause (i) of Section 1.55) and (x) any margin by the Sublicensee (calculated as such Sublicensee’s
Net Sales of the Licensed Product to Third Parties less its cost for having acquired the precursor of the Compound), or (y) [*]
of such Sublicensee’s Net Sales of the Licensed Product to Third Parties, whichever of (x) or (y) is the lower.


 


[*].


 


		6.4	Royalty Term. Neoprobe’s obligation to pay royalties shall commence, on a country-by-country basis, with respect
to each separate Licensed Product, on the Effective Date and shall expire, on a country-by-country basis, with respect to each
separate Licensed Product on the later to occur of: (a) the tenth (10th) anniversary of the First Commercial Sale of such Licensed
Product in such country, and (b) such time as there is no longer (i) any Valid Claim of a Licensed Patent or Joint Patent that
claims or covers the Exploitation of such Licensed Product in such country or (ii) any Data Exclusivity with respect to such Licensed
Product in such country, provided that, in case only protection under (ii) remains, Neoprobe retains exclusive license rights from
AstraZeneca for the duration of Data Exclusivity and there has been no generic version of the Licensed Product introduced in such
country.



 


		6.5	Sales Subject to Royalties. Sales between Neoprobe, its Affiliates and Sublicensees shall not be subject to royalties
hereunder. Royalties shall be calculated on Neoprobe’s, its Affiliates’ or, subject to Section 6.3, its Sublicensees’
sale of the Licensed Products to a Third Party. Royalties shall be payable only once for any given batch of the Licensed Products.
For purposes of determining Net Sales, the Licensed Product shall be deemed to be sold when invoiced.



 



    	 	Page 25 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 










 


		6.6	Royalty Payments. The royalties shall be calculated quarterly as of the last day of March, June, September and December
respectively, for the Calendar Quarter ending on that date. Neoprobe shall pay the royalties in conjunction with the delivery of
a written report to AstraZeneca within sixty (60) days after the end of each Calendar Quarter that shows, with respect to each
country and each Licensed Product, the sales volume, gross sales amount and Net Sales of the Licensed Products during such Calendar
Quarter.



 


		6.7	Records Retention; Audit.



 


		6.7.1	Neoprobe shall, and shall cause its Affiliates and Sublicensees to, keep complete and accurate records or books of account
in accordance with applicable generally accepted accounting principles showing the information that is necessary for the accurate
determination of the royalties due hereunder with respect to the sale of such Licensed Product. Such
books and records shall be retained by Neoprobe and its Affiliates and Sublicensees until the later of (a) five (5) years after
the end of the period to which such books and records pertain, and (b) the expiration of the applicable tax statute of limitations
(or any extensions thereof), or for such longer period as may be required by Applicable Law.



 


		6.7.2	Upon the written request of AstraZeneca, Neoprobe shall, and shall cause its Affiliates and Sublicensees to, permit a certified
public accountant or a person possessing similar professional status and associated with an independent accounting firm acceptable
to the Parties to inspect during regular business hours and no more than once a year and going back no more than three (3) years
preceding the current year, all or any part of Neoprobe’s records and books necessary to check the accuracy of the royalties
paid. The accounting firm shall enter into appropriate obligations with Neoprobe to treat all information it receives during its
inspection in confidence. The accounting firm shall disclose to AstraZeneca and Neoprobe only whether the royalty reports are correct
and details concerning any discrepancies, but no other information shall be disclosed to AstraZeneca. The cost of such review,
including the charges of any accounting firm, shall be paid by AstraZeneca, except that if the royalties have been understated
by more than three percent (3%), the costs shall be paid by Neoprobe. 



 



    	 	Page 26 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


 


		6.8	Mode of Payment. All payments set forth in this Article 6 shall be remitted by wire transfer to the following bank
account of AstraZeneca or such other account as AstraZeneca may designate in writing to Neoprobe:



 


[*]


 


		6.9	Currency. All payments required under this Article 6 shall be made in U.S. Dollars. If any currency conversion
shall be required in connection with any payment hereunder, such conversion shall be made by using the arithmetic mean of the exchange
rates for the purchase of U.S. dollars as published in The Wall Street Journal, Eastern Edition, on the first business day
of each Calendar Quarter and the last business day of each month in the Calendar Quarter to which such payments relate.



 


		6.10	Taxes.



 


		6.10.1	General. The royalties, milestones and other amounts payable by one Party (the “Payer”) to the other
Party (the “Payee”) pursuant to this Agreement (“Payments”) shall not be reduced on account
of any taxes unless required by Applicable Law. The Payee alone shall be responsible for paying any and all taxes (other than withholding
taxes required by Applicable Law to be paid by the Payer) levied on account of, or measured in whole or in part by reference to,
any Payments it receives. The Payer shall deduct or withhold from the Payments any taxes that it is required by Applicable Law
to deduct or withhold. Notwithstanding the foregoing, if the Payee is entitled under any applicable tax treaty to a reduction of
rate of, or the elimination of, applicable withholding tax, it may deliver to the Payer or the appropriate governmental authority
(with the assistance of the Payer to the extent that this is reasonably required and is expressly requested in writing) the prescribed
forms necessary to reduce the applicable rate of withholding or to relieve the Payer of its obligation to withhold tax, and the
Payer shall apply the reduced rate of withholding, or dispense with withholding, as the case may be, provided that the Payer
has received evidence, in a form reasonably satisfactory to the Payer, of the Payee’s delivery of all applicable forms (and,
if necessary, its receipt of appropriate governmental authorization) at least fifteen (15) days prior to the time that the Payments
are due. If, in accordance with the foregoing, the Payer withholds any amount, it shall pay to the Payee the balance when due,
make timely payment to the proper taxing authority of the withheld amount, and send to the Payee proof of such payment within sixty
(60) days following that payment. For purposes of this Agreement, the stated amount of the Payments payable by Neoprobe shall include
any sales tax that AstraZeneca may be required to collect.



 



    	 	Page 27 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		6.10.2	Indirect Taxes. Notwithstanding anything contained in Section 6.10.1, this Section 6.10.2 shall apply with
respect to Indirect Taxes. All Payments are exclusive of Indirect Taxes. If any Indirect Taxes are chargeable in respect of any
Payments, Neoprobe shall pay Indirect Taxes at the applicable rate in respect of any such Payments following the receipt of an
Indirect Taxes invoice in the appropriate form issued by AstraZeneca in respect of those Payments, such Indirect Taxes to be payable
on the later of the due date of the payment of the Payments to which such Indirect Taxes relates and sixty (60) days after the
receipt by Neoprobe of the applicable invoice relating to that Indirect Taxes payment.



 


		6.11	Interest on Late Payment. If any payment due to AstraZeneca under this Agreement is overdue then Neoprobe shall pay
interest thereon (before and after any judgment) at an annual rate (but with interest accruing on a daily basis) of two percentage
points above the base lending rate of LIBOR from time to time published in respect of the period starting on the due date of payment
and ending on the actual date of payment, such interest to run from the date upon which payment of such sum became due until payment
thereof in full together with such interest.



 


		7	Supply to AstraZeneca



 


Neoprobe
shall Manufacture for and supply the Compound or Licensed Product to AstraZeneca [*] for
such Manufacturing for the purposes of AstraZeneca utilising its retained rights regarding the Licensed Patents, Licensed Know
How, Joint Patent and Joint Know-How hereunder, provided, however, that (i) AstraZeneca shall give ninety (90) days’ written
notice to Neoprobe regarding any requested shipment, (ii) any such Compound or Licensed Product supplied to AstraZeneca shall meet
appropriate AstraZeneca quality standards and any standard required by Applicable Law and relevant Health Registration Approvals,
and (iii) Neoprobe shall not have the obligation to undertake any efforts to apply for, obtain or maintain Regulatory Approvals
to allow the Manufacture or supply of such Compound or Licensed Product other than, for the avoidance of doubt, from what follows
from Neoprobe’s obligations under Sections 5.2.1. Well in advance of the first shipment the Parties shall specify relevant
quality standards for such purpose. 


 



    	 	Page 28 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


 


		8	Ownership of Intellectual Property and Regulatory Documentation



 


		8.1	Ownership of Inventions. Subject to Sections 8.2 and 8.3 and the licence grants to Neoprobe under Section 3.1,
as between the Parties, each Party shall own and retain all right, title and interest in and to any and all: (a) Information and
other inventions that are conceived, discovered, developed or otherwise made, as necessary to establish authorship, inventorship
or ownership under Applicable Law, by or on behalf of such Party under or in connection with this Agreement (or its Affiliates
or its licensees or sublicensees), whether or not patented or patentable, and any and all Patent and Intellectual Property Rights
with respect thereto, except to the extent that any such Information or other inventions, or any Patent or Intellectual Property
Rights with respect thereto, are Joint Know-How or Joint Patents, and (b) other Information or other inventions, and Patent and
Intellectual Property Rights that are owned or otherwise Controlled (other than pursuant to the licence grants set forth in Section 3.1)
by such Party, its Affiliates or its licensees or sublicensees.



 


		8.2	Ownership of Licensed Patents and Licensed Know-How. Subject to the licence grants to Neoprobe under Section 3.1,
as between the Parties, AstraZeneca shall own and retain all right, title and interest in and to all Licensed Patents and Licensed
Know-How.



 


		8.3	Ownership of Regulatory Documentation. Neoprobe shall own all right, title and interest in and to all Regulatory Documentation,
including Regulatory Documentation created by Neoprobe in performance of Neoprobe's obligations under this Agreement, subject to
the Right of Reference to assigned Regulatory Documentation granted to AstraZeneca in Section 3.4.



 



    	 	Page 29 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		8.4	Ownership of Joint Patents and Joint Know-How. The Parties shall each own an equal, undivided interest in any and all
(a) Information that is conceived, discovered, developed or otherwise made, as necessary to establish authorship, inventorship
or ownership under Applicable Law, jointly by or on behalf of AstraZeneca (or its Affiliates), on the one hand, and Neoprobe (or
its Affiliates or its Sublicensees), on the other hand, in connection with the work conducted under or in connection with this
Agreement, whether or not patented or patentable (the “Joint Know-How”), and (b) Patents (the “Joint
Patents”) and Intellectual Property Rights with respect thereto. Each Party shall promptly disclose to the other Party
in writing, and shall cause its Affiliates, licensees and sublicensees to so disclose, the development, making, conception or reduction
to practice of any Joint Know-How or Joint Patents; provided, however, that none of AstraZeneca, Neoprobe or any
of their respective Affiliates or sublicensees shall Exploit any Joint Patent or Joint Know-How outside the scope of this Agreement
without the consent of the other Party, provided that AstraZeneca shall have the right to Exploit the Joint Patents and the Joint
Know-How outside the Field and for the purpose of utilising its retained rights under Section 3.1.2 in its sole discretion, without
the consent of Neoprobe, and provided further that Neoprobe shall not assign, pledge, encumber or otherwise transfer
any of its rights in any Joint Know-How or Joint Patents without AstraZeneca’s prior written consent.



 


		9	Adverse Event Reporting and Product Recall



 


		9.1	Adverse Event Reporting. Neoprobe shall undertake all responsibility for all pharmacovigilance activities related to
the safety of each Licensed Product and will be responsible for the global safety database regarding the Licensed Product provided,
however, that AstraZeneca shall report adverse events regarding the Licensed Product in accordance with its relevant Standard Operation
Procedures observed in the course of its use of the Licensed Product hereunder. Within ninety (90) days
of the Effective Date, the Parties will enter into a separate safety agreement setting forth the principles now laid down. In the
event of any inconsistency between the provisions of the Safety Agreement and the provisions of this Agreement, the provisions
of this Agreement shall prevail. 



 


		9.2	Notification and Recall. In the event that any government agency or authority issues or requests a recall or takes similar
action in connection with the Compounds or the Licensed Products, or in the event either Party determines that an event, incident
or circumstance has occurred that may result in the need for a recall or market withdrawal, the Party notified of or desiring such
recall or market withdrawal shall promptly advise the other Party thereof by telephone or facsimile. Following notification of
a recall, Neoprobe shall decide and have control of whether to conduct a recall or market withdrawal (except in the case of a government-mandated
recall) in the Territory and the manner in which any such recall or market withdrawal shall be conducted. Neoprobe shall bear the
expenses of any recall of a Licensed Product;



 



    	 	Page 30 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		10	Confidentiality & Non-Disclosure



 


		10.1	Defined; General Obligations.



 


		10.1.1	In this Agreement, “Confidential Information” shall, subject to Section 10.3, mean any and all data,
results, know-how (including the Licensed Know-How), plans, business information and other Information, whether oral or in writing
or in any other form, disclosed before, on or after the date of this Agreement by one Party to the other Party, including the terms
of this Agreement. At all times during the term of this Agreement and for a period of five (5) years following termination or expiration
hereof, each Party (the “Receiving Party”) shall, and shall cause its officers, directors, employees, agents,
Affiliates and Sublicensees to, keep confidential and not publish or otherwise disclose and not use, directly or indirectly, for
any purpose, any Confidential Information provided to it by the other Party (the “Disclosing Party”), except
to the extent such disclosure or use is expressly permitted by the terms of this Agreement or is reasonably necessary for the performance
of this Agreement.



 


		10.2	Permitted Disclosures. Each Party may disclose Confidential Information to the extent that such disclosure is:



 


		10.2.1	made in response to a valid order of a court of competent jurisdiction or other competent authority; provided, however,
that the Receiving Party shall first have given notice to the Disclosing Party and given the Disclosing Party a reasonable opportunity
to quash any such order or obtain a protective order requiring that the Confidential Information and documents that are the subject
of such order be held in confidence by such court or authority or, if disclosed, be used only for the purpose for which the order
was issued; and provided further that if such order is not quashed or a protective order is not obtained, the Confidential
Information disclosed in response to such court or governmental order shall be limited to that information that is legally required
to be disclosed in response to such court or governmental order;



 



    	 	Page 31 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		10.2.2	made by the Receiving Party to a Health Authority as may be necessary or reasonably useful in connection with any filing, application
or request for a Health Registration Approval; provided, however, that reasonable measures shall be taken to assure
confidential treatment of such information, to the extent such protection is available;



 


		10.2.3	made by the Receiving Party to a patent authority as may be necessary or reasonably useful for purposes of obtaining or enforcing
a Patent (consistent with the terms and conditions of Article 15); provided, however, that reasonable measures
shall be taken to assure confidential treatment of such information, to the extent such protection is available;



 


		10.2.4	otherwise required by law; provided, however, that the Receiving Party shall (a) provide the Disclosing Party
with reasonable advance notice of and an opportunity to comment on any such required disclosure, (b) if requested by the Disclosing
Party, seek confidential treatment with respect to any such disclosure to the extent available, and (c) use good faith efforts
to incorporate the comments of the Disclosing Party in any such disclosure or request for confidential treatment; or



 


		10.2.5	made by either Party or its Affiliates or Sublicensees to Third Parties as may be necessary or reasonably useful in
connection with the Exploitation or Manufacture of the Compounds or the Licensed Products as contemplated by this Agreement, including
permitted subcontracting or sublicensing transactions in connection therewith provided all such disclosures are subject to obligations
of confidentiality substantially similar to the terms set out in this Article 10.



 


Notwithstanding the foregoing, in the event that
either Party is required by Applicable Law or the requirements of a national securities exchange or another similar regulatory
body to disclose this Agreement, in whole or in part, the Parties shall reasonably agree on a redacted version of this Agreement
as necessary to protect the Confidential Information of the Parties prior to making such disclosure.


 


		10.3	Exclusions. Notwithstanding the foregoing, Confidential Information shall not include any information that:



 



    	 	Page 32 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		10.3.1	is or hereafter becomes part of the public domain by public use, publication, general knowledge or the like through no wrongful
act, fault or negligence on the part of the Receiving Party;



 


		10.3.2	can be demonstrated by documentation or other competent proof to have been in the Receiving Party’s or its Affiliates’
possession prior to disclosure by the Disclosing Party;



 


		10.3.3	is subsequently received by the Receiving Party or its Affiliates from a Third Party who is not bound by any obligation of
confidentiality with respect to said information;



 


		10.3.4	is generally made available to Third Parties by the Disclosing Party without restriction on disclosure; or



 


		10.3.5	is independently developed by or for the Receiving Party or its Affiliates without reference to the Disclosing Party’s
Confidential Information.



 


Specific aspects or details of Confidential Information
shall not be deemed to be within the public domain or in the possession of the Receiving Party merely because the Confidential
Information is embraced by more general information in the public domain or in the possession of the Receiving Party. Further,
any combination of Confidential Information shall not be considered in the public domain or in the possession of the Receiving
Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the
Receiving Party unless the combination and its principles are in the public domain or in the possession of the Receiving Party.


 



    	 	Page 33 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


 


		10.4	Use of Name. Neither Party shall mention or otherwise use the name, insignia, symbol, trademark, trade name or logotype
of the other Party or its Affiliates in any publication, press release, promotional material or other form of publicity without
the prior written consent of the other Party (which shall not be unreasonably withheld or delayed), except for those disclosures
for which consent has previously been obtained. The restrictions imposed by this Section 10.4 shall not prohibit either Party
from making any disclosure identifying the other Party that is required by Applicable Law or the requirements of a national securities
exchange or another similar regulatory body, provided that any such disclosure shall be governed by this Article 10. Further,
the restrictions imposed on each Party under this Section 10.4 are not intended, and shall not be construed, to prohibit a
Party from identifying the other Party in its internal business communications, provided that any Confidential Information in such
communications remains subject to this Article 10. Notwithstanding the foregoing, without prior consent, (i) upon execution
of this Agreement the Parties agree to issue the press release, attached as Exhibit 2, concerning this Agreement and the relationship
established hereby; (ii) Neoprobe may make announcements with respect to any material developments regarding Licensed Products
or Compounds, including but not limited to, those arising out of the activities contemplated herein and that are material; and
(iii) Neoprobe may make announcements with respect to the status of its relationship with AstraZeneca, including but not limited
to, achievement of any milestones hereunder; provided, however, with respect to clauses (i) and (ii) that Neoprobe may not use
AstraZeneca’s name in such announcements unless such use has been approved by the JSC.



 


		10.5	Publications. Each Party shall submit to the JSC for review and approval all proposed academic, scientific and medical
publications and public presentations relating to a Licensed Product, a Compound, or any Development Activities for review in connection
with preservation of Patent rights and trade secrets and/or determination of whether Confidential Information should be modified
or deleted from the proposed publication or public presentation. Written copies of such proposed publications and presentations
shall be submitted to the JSC no later than fifteen (15) days before submission for publication or presentation and the JSC shall
provide its comments with respect to such publications and presentations within ten (10) days after submission. The review period
may be extended for an additional fifteen (15) days if a representative of such JSC can demonstrate a reasonable need for such
extension, including but not limited to, the preparation and filing of Patent applications. By mutual agreement of the Parties,
this period may be further extended. The Parties will each comply with standard academic practice regarding authorship of scientific
publications and recognition of contribution of other parties in any such publications or presentations.



 



    	 	Page 34 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		10.6	Equitable Relief. Neoprobe acknowledges and agrees that the restrictions set forth in this Article 10 are reasonable
and necessary to protect the legitimate interests of AstraZeneca and that AstraZeneca would not have entered into this Agreement
in the absence of such restrictions, and that any breach or threatened breach of any provision of this Article 10 will result
in irreparable injury to AstraZeneca for which there will be no adequate remedy at law. In the event of a breach or threatened
breach of any provision of this Article 10, AstraZeneca shall be authorised and entitled to obtain from any court of competent
jurisdiction injunctive relief, whether preliminary or permanent, specific performance and an equitable accounting of all earnings,
profits and other benefits arising from such breach, which rights shall be cumulative and in addition to any other rights or remedies
to which AstraZeneca may be entitled in law or equity. Neoprobe agrees to waive any requirement that AstraZeneca (a) post a bond
or other security as a condition for obtaining any such relief, and (b) show irreparable harm, balancing of harms, consideration
of the public interest or inadequacy of monetary damages as a remedy. Nothing in this Section 10.6 is intended, or should
be construed, to limit AstraZeneca’s right to equitable relief or any other remedy for a breach of any other provision of
this Agreement.



 


		11	Trademarks and INN



 


Neoprobe shall have the sole right to select the
Trademarks and International Non-Proprietary Name (“INN”) for the marketing and sale of the Licensed Products
in the Territory. Neoprobe shall own such Trademarks and INN and all rights and goodwill with respect thereto. 


 


		12	Representations and Warranties



 


		12.1	Representations, Warranties and Covenants. Each Party hereby represents, warrants and covenants to the other Party as
of the Effective Date as follows:



 


		12.1.1	Corporate Authority. Such Party (a) has the power and authority and the legal right to enter into this Agreement and
to perform its obligations hereunder, and (b) has taken all necessary action on its part required to authorize the execution and
delivery of this Agreement and the performance of its obligations hereunder. This Agreement has been duly executed and delivered
on behalf of such Party and constitutes a legal, valid and binding obligation of such Party and is enforceable against it in accordance
with its terms subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement
of creditor rights and judicial principles affecting the availability of specific performance and general principles of equity,
whether enforceability is considered a proceeding at law or equity.



 



    	 	Page 35 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		12.1.2	Litigation. Such Party is not aware of any pending or threatened litigation (and has not received any communication)
that alleges that such Party’s activities related to this Agreement have violated, or that by conducting the activities as
contemplated herein such Party would violate, any of the intellectual property rights of any other party.



 


		12.1.3	Consents, Approvals, etc. All necessary consents, approvals and authorizations of all Health Authorities and other Persons
required to be obtained by such Party in connection with the execution and delivery of this Agreement and the performance of its
obligations hereunder have been obtained.



 


		12.1.4	Conflicts. The execution and delivery of this Agreement and the performance of such Party’s obligations hereunder
(a) do not conflict with or violate any provision of the articles of incorporation, bylaws or any similar instrument of such Party
in any material way, and (b) do not conflict with, violate, or breach or constitute a default or require any consent under, any
contractual obligation or court or administrative order by which such Party is bound.



 


		12.1.5	Debarment. No such Party nor any of its Affiliates has been debarred or is subject to debarment and neither such Party
nor any of its Affiliates will use in any capacity, in connection with the services to be performed under this Agreement, any Person
who has been debarred pursuant to Section 306 of the Federal Food, Drug, and Cosmetic Act, as amended, or who is the subject of
a conviction described in such section. Each Party will inform the other Party in writing immediately if it or any Person who is
performing services hereunder is debarred or is the subject of a conviction described in Section 306, or if any action, suit, claim,
investigation or legal or administrative proceeding is pending or, to such Party’s knowledge, is threatened, relating to
the debarment or conviction of such Party or any Person performing services hereunder.



 


		12.1.6	Compliance with Applicable Laws. Each Party shall use reasonable efforts to comply with all Applicable Laws in exercising
its rights and complying with its obligations pursuant to this Agreement.



 



    	 	Page 36 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		12.1.7	Anti-Bribery and Anti-Corruption. Each Party agrees, on behalf of itself, its officers, directors and employees and
on behalf of its Affiliates, agents, representatives, consultants and subcontractors hired in connection with the subject matter
of this Agreement (together with such Party, the “Party Representatives”) that for the performance of its obligations
hereunder:



 


The Party Representatives shall not directly or
indirectly pay, offer or promise to pay, or authorize the payment of any money, or give, offer or promise to give, or authorize
the giving of anything else of value, to:


 


		(1)	any Government Official in order to influence official action;



 


		(2)	any Person (whether or not a Government Official) (i) to influence such Person to act in breach of a duty of good faith, impartiality
or trust (“acting improperly”), (ii) to reward such Person for acting improperly, or (iii) where such Person would
be acting improperly by receiving the money or other thing of value;



 


		(3)	any other Person while knowing or having reason to know that all or any portion of the money or other thing of value will be
paid, offered, promised or given to, or will otherwise benefit, a Government Official in order to influence official action for
or against either Party in connection with the matters that are the subject of this Agreement; or



 


		(4)	any Person to reward that Person for acting improperly or to induce that Person to act improperly.



 


Party Representatives
shall not, directly or indirectly, solicit, receive or agree to accept any payment of money or anything else of value in violation
of the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, or any other applicable anti-corruption
laws and laws for the prevention of fraud, racketeering, money laundering or terrorism.


 


		12.2	Additional Representations and Warranties of AstraZeneca. As of the Effective Date, AstraZeneca represents and warrants
to Neoprobe that:



 


		12.2.1	AstraZeneca Controls the Patents listed on Schedule 4 and Licensed Know-How, and is entitled to grant the licences specified
herein.



 



    	 	Page 37 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		12.2.2	To AstraZeneca’s Knowledge, the Licensed Patents are being procured from the respective Patent Offices in accordance
with Applicable Law.



 


		12.2.3	AstraZeneca has no Knowledge from which it could be reasonably inferred that the Licensed Patents or the Licensed Know-How
existing as of the Effective Date are invalid or unenforceable, that the Patent applications included in such Licensed Patents
will not proceed to grant, or that the Exploitation of the Compounds or Licensed Products as contemplated by this Agreement infringes
any Patent owned by any Third Party. [*]. No claim or litigation has been brought or threatened by any Person alleging that (a)
the Licensed Patents or the Licensed Know-How are invalid or unenforceable or (b) the Exploitation of the Compounds or Licensed
Products as contemplated by this Agreement infringes any Patent owned by any Third Party.



 


		12.2.4	To AstraZeneca’s Knowledge the Licensed Patents listed on Schedule 4 represent all Patents within AstraZeneca’s
Control relating to the Compounds and Licensed Products as of the Effective Date.



 


		12.2.5	Subject to such rights granted for the conduct of ISS Studies in accordance with what is set forth in Schedule 6 [*], AstraZeneca
has not previously granted any Person rights in the Licensed Patents, Licensed Know-How, Compounds or the Licensed Products (including
by granting any covenant not to sue with respect thereto) that are inconsistent with the rights and licences granted to Neoprobe
under this Agreement.



 


		12.2.6	To AstraZeneca’s Knowledge the Regulatory Documentation assigned to Neoprobe under this Agreement is accurate
and any Health Registration Approvals therein were obtained in accordance with Applicable Law.



 


		12.3	DISCLAIMER OF WARRANTY. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN SECTIONS 12.1 AND 12.2, ASTRAZENECA
MAKES NO REPRESENTATIONS AND GRANTS NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE,
AND ASTRAZENECA SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY
OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE
NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.



 



    	 	Page 38 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		13	Indemnity



 


		13.1	Indemnification of AstraZeneca. In addition to any other remedy available to AstraZeneca, Neoprobe shall indemnify,
defend and hold harmless AstraZeneca, its Affiliates and its and their directors, officers and employees in full and on demand,
from and against any and all Losses incurred by them to the extent resulting from arising out of or in connection with any claims
made or suits brought by a Sublicensee or Third Party (collectively, “Third Party Claims”) against AstraZeneca,
its Affiliates or its or their directors, officers or employees that arise or result from (a) any intentional misconduct or negligence
on the part of Neoprobe or its Affiliates in performing any activity contemplated by this Agreement, (b) the breach by Neoprobe
of any of its representations, warranties, covenants or obligations under this Agreement, or (c) the Exploitation by Neoprobe,
its Affiliates or Sublicensees of the Licensed Products (including any claims for death, personal injury or infringement of a Third
Party’s rights) ), except to the extent any of (a) through (c) resulting from the negligence or intentional misconduct of
AstraZeneca.



 


		13.2	Indemnification of Neoprobe. In addition to any other remedy available to Neoprobe, AstraZeneca shall indemnify, defend
and hold harmless Neoprobe, its Affiliates and its and their directors, officers and employees in full and on demand, from and
against any and all Losses incurred by them to the extent resulting from or arising out of or in connection with any Third Party
Claims against Neoprobe, its Affiliates or its or their directors, officers or employees that arise or result from (a) any intentional
misconduct or negligence on the part of AstraZeneca or its Affiliates in performing any activity contemplated by this Agreement,
or (b) the breach by AstraZeneca of any of its representations, warranties, covenants or obligations under this Agreement, except
to the extent any of (a) or (b) resulting from the negligence or intentional misconduct by Neoprobe.



 



    	 	Page 39 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		13.3	Notice of Claim.  An Indemnified Party shall give the Indemnifying Party prompt written notice of any Loss or
discovery of fact upon which such Indemnified Party intends to base a request for indemnification under Section 13.1 or 13.2
(an “Indemnification Claim Notice”). In no event shall the Indemnifying Party be liable for any Loss that results
from any delay in providing the Indemnification Claim Notice. Each Indemnification Claim Notice shall contain a description of
the claim and the nature and amount of the Loss claimed (to the extent that the nature and amount of such Loss is known at such
time). The Indemnified Party shall furnish promptly to the Indemnifying Party copies of all papers and official documents received
in respect of any such Loss. For the avoidance of doubt, all indemnification claims in respect of a Party, its Affiliates or their
respective directors, officers, employees and agents (each, an “Indemnitee”) shall be made solely by such Party
to this Agreement.



 


		13.4	Indemnification Procedures. The obligations of an Indemnifying Party under this Article 13 shall be governed by
and contingent upon the following:



 


		13.4.1	Assumption of Defence. At its option, the Indemnifying Party may assume the defence of any Third Party Claim by giving
written notice to the Indemnified Party within fourteen (14) days after the Indemnifying Party’s receipt of an Indemnification
Claim Notice. The assumption of the defence of a Third Party Claim by the Indemnifying Party shall not be construed as an acknowledgement
that the Indemnifying Party is liable to indemnify any Indemnitee in respect of the Third Party Claim, nor shall it constitute
a waiver by the Indemnifying Party of any defences it may assert against any Indemnified Party’s claim for indemnification.



 


		13.4.2	Control of Defence. Upon the assumption of the defence of a Third Party Claim by the Indemnifying Party:



 


		(a)	the Indemnifying Party may appoint as lead counsel in the defence of the Third Party Claim any legal counsel selected by the
Indemnifying Party, which shall be reasonably acceptable to the Indemnified Party, and



 


		(b)	Except as expressly provided in Section 13.4.3, the Indemnifying Party shall not be liable to the Indemnified Party for
any legal expenses subsequently incurred by such Indemnified Party or any Indemnitee in connection with the analysis, defence or
settlement of the Third Party Claim. In the event that it is ultimately determined that the Indemnifying Party is not obligated
to indemnify, defend or hold harmless an Indemnitee from and against the Third Party Claim, the Indemnified Party shall reimburse
the Indemnifying Party for any and all costs and expenses (including lawyers’ fees and costs of suit) and any Loss incurred
by the Indemnifying Party in its defence of the Third Party Claim with respect to such Indemnified Party or Indemnitee.



 



    	 	Page 40 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		13.4.3	Right to Participate in Defence. Without limiting Section 13.4.1 or 13.4.2, any Indemnitee shall be entitled
to participate in, but not control, the defence of a Third Party Claim and to retain counsel of its choice for such purpose; provided,
however, that such retention shall be at the Indemnitee’s own expense unless, (a) the Indemnifying Party has failed
to assume the defence and retain counsel in accordance with Section 13.4.1 (in which case the Indemnified Party shall control
the defence), or (b) the interests of the Indemnitee and the Indemnifying Party with respect to such Third Party Claim are sufficiently
adverse to prohibit the representation by the same counsel of both parties under Applicable Law, ethical rules or equitable principles.



 


		13.4.4	Settlement. With respect to all Losses, where the Indemnifying Party has assumed the defence of a Third Party Claim
in accordance with Section 13.4.1, the Indemnifying Party shall have authority to consent to the entry of any judgement, enter
into any settlement or otherwise dispose of such Losses, provided that it obtains the prior written consent of the Indemnified
Party (which consent shall not be unreasonably withheld, refused, conditioned, or delayed). Regardless of whether the Indemnifying
Party chooses to defend or prosecute any Third Party Claim, no Indemnified Party or Indemnitee shall admit any liability with respect
to, or settle, compromise or discharge, any Third Party Claim without the prior written consent of the Indemnifying Party, which
consent shall not be unreasonably withheld, refused, conditioned, or delayed. The Indemnifying Party shall not be liable for any
settlement or other disposition of Loss by an Indemnified Party or an Indemnitee that is reached without the written consent of
the Indemnifying Party. The Indemnifying Party shall not, without the written consent of the Indemnified Party (which consent shall
not be unreasonably withheld, refused, conditioned, or delayed), effect any settlement of any such Third Party Claim, unless such
settlement includes an unconditional release of the Indemnified Party from all liability on such claim.



 



    	 	Page 41 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		13.4.5	Cooperation. If the Indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party shall,
and shall cause each other Indemnitee, to cooperate in the defence or prosecution thereof and shall furnish such records, information
and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be
reasonably requested in connection therewith. Such cooperation shall include access during normal business hours by the Indemnifying
Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third
Party Claim, and making the Indemnified Party, the Indemnitees and its and their employees and agents available on a mutually convenient
basis to provide additional information and explanation of any records or information provided, and the Indemnifying Party shall
reimburse the Indemnified Party for all of its related reasonable out-of-pocket expenses.



 


		13.4.6	Expenses. Except as expressly provided above, the reasonable and verifiable costs and expenses, including fees and disbursements
of counsel, incurred by the Indemnified Party in connection with any claim shall be reimbursed on a Calendar Quarter basis by the
Indemnifying Party, without prejudice to the Indemnifying Party’s right to contest the Indemnified Party’s right to
indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the
Indemnified Party.



 


		13.5	LIMITATION ON DAMAGES. EXCEPT IN CIRCUMSTANCES OF GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT BY A PARTY OR ITS AFFILIATES,
OR WITH RESPECT TO THIRD PARTY CLAIMS UNDER SECTION 13.1 OR 13.2, NO PARTY OR ANY OF ITS AFFILIATES SHALL BE LIABLE FOR
SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, OR FOR LOST PROFITS, WHETHER IN CONTRACT, WARRANTY, NEGLIGENCE, TORT, STRICT
LIABILITY OR OTHERWISE, ARISING OUT OF (a) THE DEVELOPMENT, MANUFACTURE, USE OR SALE OF ANY LICENSED PRODUCT OR COMPOUND DEVELOPED,
MANUFACTURED OR MARKETED HEREUNDER, or (b) ANY BREACH OF OR FAILURE TO PERFORM ANY OF THE PROVISIONS OF THIS AGREEMENT.



 



    	 	Page 42 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		13.6	Insurance. Neoprobe shall have and maintain such type and amounts of liability insurance covering the Manufacture, supply,
use and sale of the Compounds and the Licensed Products as is normal and customary in the pharmaceutical industry generally for
Persons similarly situated, and shall upon request provide AstraZeneca with a copy of its policies of insurance in that regard,
along with any amendments and revisions thereto.



 


		14	Maintenance and Prosecution of Patents



 


		14.1	Licensed Patents. Subject to Section 14.3, AstraZeneca shall have the right, but not the obligation, using legal
counsel of its choosing, to file, prosecute (including any interferences, reissue proceedings and re-examinations) and maintain
the Licensed Patents throughout the world; provided, however, that Neoprobe shall reimburse AstraZeneca for all reasonable
out-of-pocket costs incurred by AstraZeneca for filing, prosecuting and maintaining the Licensed Patents in the Major Markets,
the Additional Markets and in any other country in the Territory, provided that Neoprobe may discontinue reimbursement of such
costs in any country other than a Major Market or an Additional Market, regarding which other country Neoprobe provides notice
in accordance with Section 14.4.



 


		14.2	Cooperation. Neoprobe shall, and shall cause its Affiliates and Sublicensees, as applicable, to, cooperate fully with
AstraZeneca in the preparation, filing, prosecution, and maintenance of the Licensed Patents. Such cooperation includes (a) promptly
executing all papers and instruments and requiring employees to execute such papers and instruments as reasonable and appropriate
so as to enable AstraZeneca to file, prosecute and maintain the Licensed Patents in any country, and (b) promptly informing AstraZeneca
of matters that may affect the preparation, filing, prosecution or maintenance of any such Licensed Patents. AstraZeneca shall
provide Neoprobe with an opportunity to review and comment on the nature and text of new or pending applications for Licensed Patents
and shall advise Neoprobe one (1) month before each patent prosecution deadline as to the response that AstraZeneca proposes to
make. If Neoprobe provides to AstraZeneca comments with respect to any such application or submission, to the extent such comments
relate to any Licensed Patents, AstraZeneca shall reasonably consider such comments, it being understood that AstraZeneca retains
the right to determine whether to comply with or incorporate such comments, if at all.



 



    	 	Page 43 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

		14.3	AstraZeneca Election not to Prosecute. If AstraZeneca elects not to pursue or continue the filing, prosecution
(including any interferences, reissue proceedings and re-examinations) or maintenance of a Licensed Patent in a particular country
or region, including by seeking any Patent term extension, restoration or the like that may be available now or in the future,
then AstraZeneca shall so notify Neoprobe promptly in writing and in good time to enable Neoprobe to meet any deadlines by which
an action must be taken to establish or preserve any such rights in such Licensed Patent in such country. Upon receipt of each
such notice by AstraZeneca or if, at any time, AstraZeneca fails to initiate any such action within thirty (30) days after a request
by Neoprobe that it do so (or, if after initiating any requested action, AstraZeneca at any time thereafter fails to diligently
pursue such action), in each case Neoprobe shall have the right, but not the obligation, at its sole cost and expense, through
counsel of its choosing, to pursue the filing or registration, or support the continued prosecution (including any interferences,
reissue proceedings and re-examinations) or maintenance, of such Licensed Patent in such country. If Neoprobe elects to pursue
such filing or registration, as the case may be, or continue such support, then Neoprobe shall notify AstraZeneca of such election
and AstraZeneca shall, and shall cause its Affiliates to, reasonably cooperate with Neoprobe in this regard. 



 


		14.4	Neoprobe Election not to Reimburse. If Neoprobe elects not to reimburse AstraZeneca for the filing, prosecution (including
any interferences, reissue proceedings and re-examinations) or maintenance costs of a Licensed Patent in any country other than
a Major Market or Additional Market, then Neoprobe shall so notify AstraZeneca promptly in writing and ninety (90) days after such
notice, Neoprobe will no longer be obligated to reimburse AstraZeneca for such costs.



 



    	 	Page 44 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

		14.5	Joint Patents. The Parties shall cooperate, and shall cause their respective Affiliates and Sublicensees, as applicable,
to cooperate, with one another with respect to the filing, prosecution (including any interferences, reissue proceedings and re-examinations)
and maintenance of all Joint Patents, including by selecting outside counsel, reasonably acceptable to the Parties, to handle such
filing, prosecution and maintenance. The Parties shall share equally in the expenses associated with the filing, prosecution (including
any interferences, reissue proceedings and re-examinations) and maintenance of all Joint Patents, except to the extent that any
such Joint Patent covers or claims a Compound or a Licensed Product, in which case Neoprobe shall bear one hundred percent (100%)
of such expenses. If a Party elects not to pursue the filing, prosecution (including any interferences, reissue proceedings and
re-examinations) or maintenance of a Joint Patent in a particular country, or to take any other action with respect to a Joint
Patent in a particular country that is necessary or reasonably useful to establish or preserve rights thereto, then in each such
case such Party shall so notify the other Party promptly in writing and in good time to enable such other Party to meet any deadlines
by which an action must be taken to establish or preserve any such rights in such Joint Patent in such country. Upon receipt of
each such notice by such other Party or if, at any time, such Party fails to initiate any such action within thirty (30) days after
a request by such other Party that it do so (or, if after initiating any requested action, such Party at any time thereafter fails
to diligently pursue such action), in each case such other Party shall have the right, but not the obligation, to pursue the filing
or registration, or support the continued prosecution or maintenance, of such Patent at its expense in such country. If such other
Party elects to pursue such filing or registration, as the case may be, or continue such support, then such other Party shall notify
such Party of such election and such Party shall, and shall cause its Affiliates, licensees and sublicensees, as applicable, to,
(x) reasonably cooperate with such other Party in this regard, and (y) promptly release or assign to such other Party, without
compensation, all right, title and interest in and to such Patent in such country; provided, however, if Neoprobe
elects not to pursue such filing or registration in a country pursuant to this sentence, any such Patent in such country assigned
to AstraZeneca hereunder shall not be included in this Agreement as a Licensed Patent.



 


		14.6	AstraZeneca Liability. To the extent that AstraZeneca is obtaining, prosecuting or maintaining a Licensed Patent or
Joint Patent or otherwise exercising its rights under this Article 14, neither AstraZeneca nor any of its employees, agents
or representatives shall be liable to Neoprobe in respect of any act, omission, default or neglect on the part of any such employee,
agent or representative in connection with such activities.



 



    	 	Page 45 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		15	Enforcement of Patents



 


		15.1	Rights and Procedures. In the event that either Party reasonably believes that a Third Party or Sublicensee may be infringing
any of the Licensed Patents or Joint Patents, such Party shall promptly notify the other Party in writing, identifying the alleged
infringer and the alleged infringement complained of and furnishing the information upon which such determination is based. AstraZeneca
shall have the first right, but not the obligation, through counsel of its choosing, to take any measures it deems appropriate
to stop such infringing activities by such Third Party or Sublicensee in any part of the Territory or to grant to the infringing
Third Party or Sublicensee adequate rights and licences necessary for continuing such activities in the Territory. However, AstraZeneca
shall not grant any rights or license under this Section 15.1 which would diminish or otherwise alter the exclusive license to
Neoprobe granted in Section 3. Upon reasonable request by AstraZeneca, Neoprobe shall give AstraZeneca all reasonable information
and assistance, including allowing AstraZeneca access to Neoprobe’s files and documents and to Neoprobe’s personnel
who may have possession of relevant information and, if necessary for AstraZeneca to prosecute any legal action, joining in the
legal action as a party at its own expense. In the event AstraZeneca fails within ninety (90) days following notice of such infringement,
or earlier notifies Neoprobe in writing of its intent not, to take commercially appropriate steps to remove any infringement of
any Licensed Patent or Joint Patent that is likely to have a material adverse effect on the sale of the Licensed Product, and AstraZeneca
has not granted the infringing Third Party or Sublicensee rights and licences to continue its otherwise infringing activities,
then unless AstraZeneca has a commercially reasonable basis in writing for not taking such steps, and provides Neoprobe with written
notice thereof within the ninety (90) day period, Neoprobe shall have the right, but not the obligation, to do so at Neoprobe’s
sole cost and expense; provided, however, that if AstraZeneca has commenced negotiations with an alleged infringer
for discontinuance of such infringement within such ninety (90) day period, AstraZeneca shall have an additional ninety (90) days
to conclude its negotiations before Neoprobe may bring suit for such infringement. Upon reasonable request by Neoprobe, AstraZeneca
shall give Neoprobe all reasonable information and assistance in connection with such suit for infringement and AstraZeneca agrees
to become a party to any such suit as required as a party being the owner of an asserted Licensed Patent, but at Neoprobe’s
sole cost and expense.



 



    	 	Page 46 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    




 


		15.2	ANDA Certification. Notwithstanding the foregoing, if either Party receives any notice of certification regarding the
Licensed Patents pursuant to the U.S. “Drug Price Competition and Patent Term Restoration Act” of 1984 (“ANDA
ACT”) claiming that any Licensed Patents are invalid or unenforceable or claiming that the Licensed Patents will not
be infringed by the Manufacture, use, marketing or sale of a product for which an application under the ANDA ACT is filed, or (b)
any equivalent or similar certification or notice in any other jurisdiction, it shall provide the other Party with a copy of such
notice of certification within ten (10) days of receipt and the Parties’ rights and obligations with respect to any legal
action as a result of such certification shall be as set forth in Section 15.1, except that AstraZeneca shall advise Neoprobe
within twenty (20) days after receiving such notice of certification, of its intent to file suit within 45 days of the notice of
certification and in the event that AstraZeneca advises that it does not intend to file such suit, Neoprobe shall have the right,
but not the obligation, to do so at Neoprobe's sole cost and expense.



 


		15.3	Costs and Expenses. Subject to what is stated in Sections 15.1 and 15.2 regarding Neoprobe filing or taking other action
at its cost and expense, each Party shall bear its own costs and expenses relating to any enforcement action pursuant to those
Sections. Any damages or other amounts collected shall be used to reimburse the Parties for their costs and expenses in making
such recovery (which amounts shall be allocated pro rata if insufficient to cover the totality of such expenses), with any remainder
being deemed “Net Sales” for which Neoprobe shall pay a royalty to AstraZeneca pursuant to Sections 6.2 and 6.2.2
with such revision that may be required taking into account by the Parties in good faith the basis for the calculation of such
damages or other amount.



 


		16	Potential Third Party Rights



 


		16.1	Third Party Licences. If the Exploitation of the Compounds or Licensed Products by Neoprobe, its Affiliates or any of
its Sublicensees infringes or misappropriates any Patent or any Intellectual Property Right of a Third Party in any country, such
that Neoprobe or any of its Affiliates or Sublicensees cannot Exploit the Compounds or the Licensed Products in such country without
infringing the Patent or Intellectual Property Right of such Third Party, then, Neoprobe shall secure from such Third Party such
rights as necessary for the Exploitation of Compounds and Licensed Products in such country. In the event that Neoprobe reasonably
determines that it is not feasible or commercially practicable for Neoprobe to secure such Third Party rights in such country,
then Neoprobe may terminate the license in such country granted under this Agreement in accordance with Section 17.2.



 



    	 	Page 47 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		16.2	Invalidity or Unenforceability Defences or Actions.



 


		16.2.1	In the event that a Third Party or Sublicensee asserts, as a defence or as a counterclaim in any infringement action under
Section 15.1, that any Licensed Patent or Joint Patent is invalid or unenforceable, then the Party pursuing such infringement
action shall promptly give written notice to the other Party. AstraZeneca shall have the first right, but not the obligation, at
its sole cost and expense through counsel of its choosing, to respond to such defence or defend against such counterclaim (as applicable)
and, if Neoprobe is pursuing the applicable infringement action under Section 15.1, Neoprobe shall allow AstraZeneca to control
such response or defence (as applicable). The Parties shall each bear fifty percent (50%) of any costs and expenses with respect
to such response or defence against such counterclaim (as applicable). If AstraZeneca determines not to respond to such defence
or defend against such counterclaim (as applicable), Neoprobe shall, at its sole cost and expense, have the right to respond to
such defence or defend against such counterclaim (as applicable).



 


		16.2.2	Similarly, if a Third Party or Sublicensee asserts, in a declaratory judgment action or similar action or claim filed by such
Third Party, that any Licensed Patent or Joint Patent is invalid or unenforceable, then the Party first becoming aware of such
action or claim shall promptly give written notice to the other Party. AstraZeneca shall have the first right, but not the obligation,
at its sole cost and expense, through counsel of its choosing, to defend against such action or claim. The Parties shall each bear
fifty percent (50%) of any costs and expenses with respect to such defence. If AstraZeneca determines not to assume such defence,
Neoprobe shall, at its sole cost and expense, have the right to defend against such action or claim.



 



    	 	Page 48 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		16.2.3	Neoprobe shall provide to AstraZeneca all reasonable assistance requested by AstraZeneca in connection with any action, claim
or suit under this Section 16.2, including allowing AstraZeneca access to Neoprobe’s files and documents and to Neoprobe’s
personnel who may have possession of relevant information. In particular Neoprobe shall promptly make available to AstraZeneca,
free of charge, all information in its possession or control that it is aware will assist AstraZeneca in responding to any such
action, claim or suit.



 


		16.3	Third Party Litigation. In the event of any actual or threatened suit against Neoprobe or its Affiliates, Sublicensees
or customers alleging that the Exploitation of Compounds or Licensed Products or that the Exploitation of a Licensed Patent or
the Licensed Know-How or any part thereof hereunder infringes the Patent or Intellectual Property Rights of any Person, Neoprobe
shall, at its sole cost and expense, assume direction and control of the defence of claims arising therefrom (including the right
to settle such claims at its sole discretion); provided, however, that Neoprobe shall obtain the written consent
of AstraZeneca prior to ceasing to defend, settling or otherwise compromising such claims with respect to any Patents and Intellectual
Property Rights of AstraZeneca.



 


		17	Term and Termination



 


		17.1	Term. This Agreement shall become effective as of the Effective Date and shall continue in effect until such time as
Neoprobe no longer owes any royalty payments to AstraZeneca under this Agreement, unless earlier terminated in accordance with
this Article 17 or Section 18.4.



 



    	 	Page 49 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

		17.2	Termination by Neoprobe. If Neoprobe reasonably determines that it is not feasible for Neoprobe to pursue the development,
launch or sale of Licensed Products due to a scientific, technical, regulatory or commercial reasons, including (a) safety or efficacy
concerns, including adverse events of the Compounds or Licensed Products, (b) concerns relating to the present or future marketability
or profitability of the Licensed Products, (c) reasons related to patent coverage, or (d) existing and anticipated competition
in the Field, which renders the Exploitation of the Licensed Product in the Field no longer commercially practicable for Neoprobe
in one or more countries, then Neoprobe shall promptly notify AstraZeneca in writing of such determination and provide AstraZeneca
with the pertinent information with respect thereto. Promptly following the receipt of such notice from Neoprobe, the Parties shall
meet and discuss in good faith any amendments to this Agreement to address Neoprobe’s concerns. If the Parties are not able
to agree on such amendments within ninety (90) days and if Neoprobe reasonably believes that it is not feasible for Neoprobe
to pursue the development, launch or sale of Licensed Products in the subject country, Neoprobe may terminate the license in such
country granted under this Agreement upon ninety (90) days’ prior written notice to AstraZeneca, and upon the effective date
of such termination the subject country shall be deleted from the Territory; provided, however, that should such country be a Major
Market, or should Neoprobe terminate the license in four or more of the Additional Markets, then upon the effective date of such
termination the entire Agreement shall terminate.



 


		17.3	Termination for Material Breach. In the event that either Party (the “Breaching Party”) shall be
in material default in the performance of any of its material obligations under this Agreement, in addition to any other right
and remedy the other Party (the “Complaining Party”) may have, the Complaining Party may terminate this Agreement
in its entirety or with respect to the country or countries to which such material default applies by sixty (60) days prior
written notice (the “Notice Period”) to the Breaching Party, specifying the breach and its claim of right to
terminate, provided always that the termination shall not become effective at the end of the Notice Period if the Breaching Party
cures the breach complained about during the Notice Period (or, if such default cannot be cured within such sixty (60)-day period,
if the Breaching Party commences actions to cure such default within the Notice Period and thereafter diligently continues such
actions, provided that such default is cured within ninety (90) days after the receipt of such notice), except in the case of a
payment default, as to which the Breaching Party shall have only a ten (10)-day cure period; provided, however, that
if Neoprobe is in default with respect to its failure to comply with its obligations under Section 5.2 in a Major Market,
AstraZeneca shall have the right to terminate this Agreement with respect to such Major Market or with respect to all of Europe
if such Major Market is in Europe, subject to the notice and cure provisions of this Section 17.3.



 



    	 	Page 50 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

		17.4	Termination by AstraZeneca. In the event that Neoprobe or any of its Affiliates or Sublicensees, anywhere in the world,
institutes, prosecutes or otherwise participates in (or in any way aids any Third Party in instituting, prosecuting or participating
in), at law or in equity or before any administrative or regulatory body, including the U.S. Patent and Trademark Office or its
foreign counterparts, any claim, demand, action or cause of action for declaratory relief, damages or any other remedy, or for
an enjoinment, injunction or any other equitable remedy, including any interference, re-examination, opposition or any similar
proceeding, alleging that any claim in a Licensed Patent is invalid, unenforceable or otherwise not patentable AstraZeneca shall
have the right to immediately terminate this Agreement, including the rights of any Sublicensees, on written notice to Neoprobe;
provided, however, that AstraZeneca may not terminate this Agreement by reason of any claim, demand or other action or proceeding
made or commenced by Neoprobe for breach of any warranty contained in Section 12.2.



 


		17.5	Change of Control In the event that Neoprobe proposes to enter into a transaction that could result in a Change of Control
(a “Proposed Transaction”), where the Person that would acquire control or is otherwise the Person that is the surviving
entity, having acquired assets or otherwise having a controlling interest following the transaction concerned as described in Section
1.8 carries out research, development or commercialisation regarding any disease-modifying agent in Alzheimer’s disease,
then Neoprobe shall provide AstraZeneca written notice of the Proposed Transaction, including the identity of the other Person
and a reasonably detailed description of the material terms of the Proposed Transaction. Upon AstraZeneca’s request Neoprobe
shall provide AstraZeneca within fourteen (14) days of such notice an analysis in reasonable detail of its assessment what impact
such Proposed Transaction would have on Neoprobe’s strategy and business targets in the area of Alzheimer’s Disease
and what, if any, impact this may have on Neoprobe’s ability or ambition to fulfil the terms and purpose of this Agreement.
AstraZeneca may within one (1) month of having received such analysis request Neoprobe to take steps which AstraZeneca deems reasonably
required to reassure AstraZeneca of Neoprobe’s intention and ability to put similar emphasis behind its Development, Commercialisation
and other efforts as prior to such Proposed Transaction. AstraZeneca shall take any analysis by Neoprobe and any suggestions by
Neoprobe on the suitability of such proposed efforts into reasonable account. Should AstraZeneca nevertheless reasonably consider
that, based on such Neoprobe’s analysis or suggestions, the performance of this Agreement by Neoprobe or its successor will
be materially jeopardised by the Proposed Transaction, then AstraZeneca may within six (6) months of having received such Neoprobe’s
notice of the Proposed Transaction as mentioned above in this Section 17.5 have the right to terminate this Agreement forthwith.
Without prejudice to Neoprobe’s obligations in this regard, should such Change of Control as described above in this Section
17.5 be proposed or take place without Neoprobe having provided notice, AstraZeneca’s right set forth in this Section 17.5
shall equally apply nevertheless and what is stated regarding the Proposed Transaction shall apply regarding such proposed or completed
transaction and the timelines shall count from the date when such transaction that could result or has resulted in a Change of
Control was publicly announced.



 



    	 	Page 51 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		17.6	Consequences of Termination.



 


		17.6.1	Return of Material; Termination of Rights. Upon expiration of this Agreement pursuant to Section 17.1 or upon termination
of this Agreement in its entirety or with respect to one or more countries by either Party pursuant to this Article 17 or
Section 18.4 each Party, at the request of the other Party, shall return, or at the election of the other Party, destroy,
and thereafter provide the other Party written certification evidencing such destruction, all data, files, records and other materials
in its or its Affiliates or, with respect to Neoprobe, Sublicensees, possession or control containing or comprising such other
Party’s Information or other Confidential Information and, in each case, to which the returning Party does not retain rights
hereunder (except one copy of which may be retained by the returning Party’s General Counsel solely for archival purposes).
All rights and licences granted to Neoprobe under this Agreement shall terminate and revert to AstraZeneca, provided that if this
Agreement is only terminated with respect to one or more countries, only the rights and licenses with respect to such country or
countries shall terminate and revert to AstraZeneca.



 


		17.6.2	Additional Consequences of Termination. In addition to the foregoing, promptly upon the termination of this Agreement
in its entirety or with respect to one or more countries by AstraZeneca pursuant to Section 17.3, 17.4, 17.5, or 18.4 or by
Neoprobe pursuant to Section 17.2:



 



    	 	Page 52 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		(a)	Neoprobe shall, and shall cause its Affiliates and Sublicensees to, disclose to AstraZeneca any and all Information, including
a copy of any documentation in tangible form, that is owned or otherwise Controlled by Neoprobe, its Affiliates or Sublicensees
at the time of termination of the Agreement that has been generated by or on behalf of Neoprobe, its Affiliates or Sublicensees
with respect to Compounds or Licensed Products and is necessary or reasonably useful to enable AstraZeneca to continue development
of a Licensed Product and the commercialisation thereof in the Territory or such country or countries, as applicable, (collectively,
the “Neoprobe Product Data”), and AstraZeneca and its Affiliates and sublicensees shall have the right to use
such Neoprobe Product Data at its discretion on an exclusive basis to Exploit Compounds and Licensed Products in the Territory
or such country or countries, as applicable, provided that any such Neoprobe Product Data shall be subject to the confidentiality
obligations set forth in Article 10.



 


		(b)	Neoprobe shall assign, and shall cause its Affiliates and Sublicensees to assign, to AstraZeneca all of their right, title
and interest in and to all Regulatory Documentation, including, for the avoidance of doubt, such Regulatory Documentation created
by Neoprobe as allowed for under Section 8.3, with respect to the Compounds and Licensed Products in the Territory or such country
or countries, as applicable, including any Health Registration Approvals and applications therefor and shall during a period of
six (6) months following the effective date of termination provide any necessary assistance to AstraZeneca during its filing or
review, if applicable, of applications submitted by Neoprobe or its Affiliates for Health Registration Approvals and for AstraZeneca’s
further maintenance of such Health Registration Approvals. In the event this Agreement is terminated only with respect to one or
more countries, Neoprobe shall have the right to reference such Regulatory Documentation to Exploit the Compounds and Licensed
Products in any remaining countries in the Territory in accordance with this Agreement.



 



    	 	Page 53 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		(c)	Neoprobe and its Affiliates shall and do hereby grant to AstraZeneca an non-exclusive, royalty-free, perpetual, irrevocable
right and licence, with the right to grant sublicenses through multiple tiers of sublicensees, under any Grant-Back Patents and,
if Neoprobe has commercialised a Licensed Product, the Neoprobe Trademarks, in each case to Exploit the Compounds and Licensed
Products in the Territory or such country or countries, as applicable. AstraZeneca shall reimburse Neoprobe for its reasonable
costs incurred in the filing, prosecution and maintenance of the Grant-Back Patents and the Neoprobe Trademarks in the Territory
or such country or countries, as applicable.



 


		(d)	In order for AstraZeneca to smoothly continue the Exploitation of the Compounds and Licensed Products in the Territory or such
country(ies), as applicable, Neoprobe shall, with the limitations set out below and for a maximum period of two (2) years, supply
AstraZeneca in a timely manner with sufficient amount of Compound or Licensed Product in the Territory or such country or countries,
as applicable, at [*]. The Parties shall separately negotiate in good faith the logistical and other terms and conditions for such
supplies.



 


		17.6.3	Remedies. Early termination of this Agreement by a Party shall in no way affect or limit such Party’s right to
claim against the other Party for any damages arising out of the breach of this Agreement.



 


		17.7	Accrued Rights; Surviving Obligations.



 


		17.7.1	Survival. The termination of this Agreement shall not relieve the Parties from performing any obligations accrued prior
to the date this Agreement terminates. Each Party’s obligations under Sections 6.6, 6.7, 6.8, 6.9, 6.10, 6.11, 17.6 and this
Section 17.7 and Articles 1, 2, 9, 11, 13, 14, 22, 23 and 30 shall survive the termination or expiration of this Agreement.



 



    	 	Page 54 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


		17.7.2	Work-in-Progress. Upon termination of this Agreement in its entirety by AstraZeneca pursuant to Section 17.3, Neoprobe
shall be entitled, during the following one hundred and eighty (180) days, to finish any work-in-progress and to sell any inventory
of the Licensed Product that remains on hand as of the date of the termination, so long as Neoprobe pays AstraZeneca the royalties
applicable to said subsequent sales in accordance with the terms and conditions set forth in this Agreement.



 


		17.8	Termination Upon Insolvency. Either Party may terminate this Agreement if, at any time, the other Party shall file in
any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency
or for reorganization or for an arrangement or for the appointment of a receiver or trustee of that Party or of its assets, or
if the other Party proposes a written agreement of composition or extension of its debts, or if the other Party shall be served
with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within sixty
(60) days after the filing thereof, or if the other Party shall propose or be a party to any dissolution or liquidation, or if
the other Party shall make an assignment for the benefit of its creditors.



 


		17.9	Rights in Bankruptcy. All rights and licences granted under or pursuant to this Agreement by AstraZeneca to Neoprobe
or by Neoprobe to AstraZeneca are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code
or analogous provisions of Applicable Law outside the United States, licences of right to “intellectual property” as
defined under Section 101 of the U.S. Bankruptcy Code or analogous provisions of Applicable Law outside the United States (hereinafter
“IP”). The Parties agree that the Parties, as licensees of such rights under this Agreement, shall retain and
may fully exercise all of their rights and elections under the U.S. Bankruptcy Code or any other provisions of Applicable Law outside
the United States that provide similar protection for IP. The Parties further agree that, in the event of the commencement of a
bankruptcy proceeding by or against a Party under the U.S. Bankruptcy Code or analogous provisions of Applicable Law outside the
United States, the other Party shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such IP
and all embodiments of such IP, which, if not already in such other Party’s possession, shall be promptly delivered to it
upon such other Party’s written request therefor.



 



    	 	Page 55 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    





 


18           Force
Majeure


 


18.1        In
this Agreement, “Force Majeure” means an event which is beyond a non-performing Party’s reasonable control,
including an act of God, act of the other Party, strike, lock-out or other industrial/labour dispute (other than at the Party prevented),
war, riot, civil commotion, terrorist act, malicious damage, epidemic, quarantine, fire, flood, storm, natural disaster or compliance
with any law or governmental order, rule, regulation or direction, whether or not it is later held to be invalid.


 


18.2        The
Force Majeure Party, shall within fifteen (15) days of the occurrence of a Force Majeure event, give notice in writing to the other
Party specifying the nature and extent of the event of Force Majeure, its anticipated duration and any action being taken to avoid
or minimize its effect. Subject to providing such notice and to Section 18.1, the Force Majeure Party shall not be liable
for delay in performance or for non-performance of its obligations under this Agreement, in whole or in part, nor shall the other
Party have the right to terminate this Agreement other than obligations to pay monies due, except as otherwise provided in this
Agreement, where non-performance or delay in performance has resulted from an event of Force Majeure. The suspension of performance
allowed hereunder shall be of no greater scope and no longer duration than is reasonably required.


 


18.3        The
Force Majeure Party shall take all steps as are necessary to (a) bring the Force Majeure event to a close or (b) find a solution
by which the Agreement may be performed despite the continuation of the event of Force Majeure.


 


18.4        If
the Force Majeure Party is prevented from performing its obligations due to a Force Majeure event for a continuous period in excess
of sixty (60) days after the date of the occurrence of the Force Majeure event, and such failure to perform would constitute a
material breach of this Agreement in the absence of such Force Majeure event, the other Party may terminate this Agreement immediately
by written notice to the Force Majeure Party, in which case neither Party shall have any liability to the other except for those
rights and liabilities that accrued prior to the date of termination.


 



    	 	Page 56 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


19          Assignment


 


This Agreement may not be assigned by either Party
in whole or in part without the prior written consent of the other Party, except that (a) AstraZeneca without such consent may
assign this Agreement and its rights and obligations hereunder to any of its Affiliates, and (b) either Party may assign this Agreement
and its rights and obligations hereunder to any successor in interest (whether by merger, acquisition, asset purchase or otherwise),
subject to AstraZeneca’s right to terminate this Agreement under Section 17.5 in case of Change of Control of Neoprobe, to
all or substantially all of the business to which this Agreement relates. AstraZeneca shall always have the right to perform any
or all of its obligations and exercise any or all of its rights under this Agreement through any of its Affiliates. 


 


20          Severability


 


If any provision of this Agreement is held to be
invalid, illegal or unenforceable, in any respect, then, to the fullest extent permitted by Applicable Law and if the rights and
obligations of any Party will not be materially and adversely affected: (a) such provision will be given no effect by the Parties
and shall not form part of this Agreement, (b) all other provisions of this Agreement shall remain in full force and effect, and
(c) the Parties shall use their best efforts to negotiate a provision in replacement of the provision held invalid, illegal or
unenforceable that is consistent with Applicable Law and achieves, as nearly as possible, the original intention of the Parties.
To the fullest extent permitted by Applicable Law, the Parties waive any provision of law that would render any provision in this
Agreement invalid, illegal or unenforceable in any respect.


 


21          Governing
Law and Arbitration


 


21.1        Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of England and Wales, excluding any conflicts
or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive
law of another jurisdiction, except for matters of intellectual property law which shall be determined in accordance with the intellectual
property laws relevant to the intellectual property in question. The United Nations Convention on the International Sale of Goods
shall not apply to this Agreement.


 



    	 	Page 57 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


21.2        Arbitration.
Any dispute arising out of or relating to this Agreement shall be settled by binding arbitration in accordance with the Rules
of Arbitration of the International Chamber of Commerce. The number of arbitrators shall be three (3), of whom each Party shall
appoint one (1). The two arbitrators so appointed will select the third and final arbitrator. The place of arbitration shall be
London. The language used in the arbitration proceedings shall be English. The proceedings, including any outcome, shall be confidential.
Nothing in this Article 21.2          will preclude any Party from seeking interim
or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or
other interim equitable relief, concerning a dispute either prior to or during any arbitration if necessary to protect the interests
of such Party or to preserve the status quo pending the arbitration proceeding. The decision of the arbitrators will be final and
binding on the Parties and any decision of the arbitrators may be enforced in any court of competent jurisdiction.


 


21.3        Attorneys’
Fees and Related Costs . In the event that any legal proceeding is brought to enforce or interpret any of the provisions of
this Agreement, the prevailing Party shall be entitled to recover its reasonable attorneys’ fees, court costs and expenses
of litigation.


 


22           Notices


 


22.1        Notice
Requirements 


 


Any notice, request, demand, waiver, consent, approval
or other communication permitted or required under this Agreement shall be in writing, shall refer specifically to this Agreement
and shall be deemed given only if delivered by hand or sent by facsimile transmission (with transmission confirmed), or
by internationally recognised overnight delivery service that maintains records of delivery, addressed to the Parties at their
respective addresses specified in Section 22.2 or to such other address as the Party to whom notice is to be given may have
provided to the other Party in accordance with this Article 22. Such Notice shall be deemed to have been given as of the date
delivered by hand or transmitted by facsimile (with transmission confirmed) or on the second business day (at the place of delivery)
after deposit with an internationally recognised overnight delivery service. This Article 22 is not intended to govern the
day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement.


 



    	 	Page 58 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


22.2        Address
for Notice 


 


For :       AstraZeneca


 


AstraZeneca AB


 


Address:         SE-151
85 Södertälje, Sweden


 


Facsimile:       +468 553
29000


 


For the attention of: Vice President SPBD CNS&Pain


 


With a copy to:


 


Address:         SE-151
85 Södertälje, Sweden


 


Facsimile:       +468 553
28812


 


For the attention of: Assistant General Counsel


 


For:       Neoprobe


 


Neoprobe Corporation


 


Address:  425 Metro Place North, Suite 300, Dublin,
OH 43017, United States


 


Facsimile:  (614) 793 - 7522


 


To the attention of:  Mark J. Pykett, President
and CEO


 


With a copy to:


 


Porter Wright Morris & Arthur


 


Address:  41 South High Street, 28th Floor, Columbus,
OH 43215


 


Facsimile:  (614) 227 - 2100


 


To the attention of:  William J. Kelly, Jr.


 


23          Standstill


 


AstraZeneca hereby agrees that from the Effective
Date and for two (2) years thereafter, unless specifically invited in writing by Neoprobe to do so, neither AstraZeneca nor any
of its Affiliates will, or will cause or knowingly permit any of its or their directors, officers, employees, investment bankers,
attorneys, accountants, or other advisors or representatives to, in any manner, directly or indirectly: (i) effect or seek, initiate,
offer or propose (whether publicly or otherwise) to effect, or cause or participate in or in any way advise, assist or encourage
any other person to effect or seek, initiate, offer or propose (whether publicly or otherwise) to effect or cause or participate
in (a) any acquisition of any securities (or beneficial ownership thereof) or assets of Neoprobe; (b) any tender or exchange offer,
merger, consolidation or other business combination involving Neoprobe; (c) any recapitalization, restructuring, liquidation, dissolution,
sale of assets, or other extraordinary transaction with respect to Neoprobe; or (d) any “solicitation” of “proxies”
(as such terms are used in the proxy rules of the United States Securities and Exchange Commission) or consents to vote any voting
securities of Neoprobe; (ii) form, join or in any way participate in a “group” (as defined under the Securities Exchange
Act of 1934, as amended) with respect to any securities of Neoprobe; (iii) otherwise act, alone or in concert with others, to seek
to control or influence the management, Board of Directors or policies of Neoprobe; (iv) take any action which might force Neoprobe
to make a public announcement regarding any of the types of matters set forth in (i) above; or (v) enter into any agreements, discussions
or arrangements with any Third Party with respect to any of the foregoing. AstraZeneca also agrees during the Term not to request
Neoprobe (or its directors, officers, employees or agents), directly or indirectly, to amend or waive any provision of this Section
23 (including this sentence). AstraZeneca represents and warrants that neither AstraZeneca nor any of its Affiliates owns, of record
or beneficially, any voting securities of Neoprobe, or any securities convertible into or exercisable for any such voting securities.
Nothing in this Section 23 shall prohibit AstraZeneca or its Affiliates from owning or making open market purchases of any voting
securities of Neoprobe, or any securities convertible into or exercisable for any such voting securities, for purposes of any 401(k)
or similar benefit plan maintained by AstraZeneca or its Affiliates for its or their employees, provided that at no time shall
the aggregate amount of securities owned under such plans of AstraZeneca and its Affiliates exceed 3% of the outstanding shares
of Neoprobe common stock (calculated on a fully diluted basis).


 



    	 	Page 59 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


Notwithstanding the foregoing, nothing in the immediately
preceding paragraph shall preclude AstraZeneca or any of its Affiliates from submitting a confidential, non-public proposal to
the Board of Directors, the Chairman of the Board of Directors or the Chief Executive Officer of Neoprobe (a) with respect to any
transaction of the type referred to in (i) of such paragraph or (b) seeking an amendment or waiver of any provision of such paragraph,
or from consulting on a confidential basis with third party advisors with respect to any such proposal. The provisions of the immediately
preceding paragraph shall cease to apply: (A) if Neoprobe or any of its Affiliates publicly announces a process designed to solicit
offers relating to, or otherwise enters into an agreement or agreement in principle with respect to, one or more transactions that,
if consummated, would result in (1) a Third Party acquiring, or having the right to acquire, beneficial ownership of twenty percent
(20%) or more of the outstanding voting securities of Neoprobe immediately after such transaction, (2) a sale of all or substantially
all of the assets of Neoprobe or any of its Affiliates for an aggregate consideration equal to more than twenty percent (20%) of
the market capitalisation of Neoprobe immediately prior to such transaction or (3) a merger, consolidation or any similar extraordinary
transaction involving Neoprobe or any of its Affiliates, which, if consummated, would result in the direct or indirect acquisition
of more than twenty percent (20%) of the outstanding voting securities of Neoprobe (other than the issuance of new securities by
Neoprobe solely in connection with a bona fide capital raising transaction), in each case ((1), (2) and (3)) from the time of such
announcement and continuing until one-hundred and twenty (120) days after such time, if any, as the Board of Directors of Neoprobe
publicly announces that such agreement or agreement in principle has terminated; (B) in the event a Third Party makes public a
tender offer or exchange offer that, if consummated, would result in such Third Party beneficially owning than twenty percent (20%)
or more of the outstanding voting securities of Neoprobe or all or substantially all of the assets of Neoprobe or any of its Affiliates
for an aggregate consideration equal to more than twenty percent (20%) of the market capitalisation of Neoprobe immediately prior
to such transaction, from the time such offer, proposal, agreement or agreement in principle is made public and continuing until
one-hundred and twenty (120) days after such tender offer or exchange offer expires or is publicly rescinded; or (C) if the Board
of Directors of Neoprobe adopts a plan of liquidation or dissolution. Further, nothing in the immediately preceding paragraph shall
prevent AstraZeneca or any of its Affiliates from acquiring securities of another pharmaceutical or biotechnology company or other
person that beneficially owns any securities of Neoprobe or any of its Affiliates.


 






    	 	Page 60 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    



 


24          Relationship
of the Parties


 


The status of a Party under this Agreement shall
be that of an independent contractor. Nothing contained in this Agreement shall be construed as creating a partnership, joint venture
or agency relationship between the Parties or, except as otherwise expressly provided in this Agreement, as granting either Party
the authority to bind or contract any obligation in the name of or on the account of the other Party or to make any statements,
representations, warranties or commitments on behalf of the other Party. All persons employed by a Party shall be employees of
such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the
account and expense of such Party.


 



    	 	Page 61 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


25          Entire
Agreement


 


This Agreement constitutes the entire agreement
between the Parties with respect to the subject matter of the Agreement. This Agreement supersedes all prior agreements, whether
written or oral, with respect to the subject matter of the Agreement. Each Party confirms that it is not relying on any statements,
representations, warranties or covenants of any person (Whether a Party to this Agreement or not) except as specifically set out
in this Agreement. Nothing in this Agreement is intended to limit or exclude any liability for fraud. All Schedules and Exhibits
referred to in this Agreement are intended to be and are hereby specifically incorporated into and made a part of this Agreement.
In the event of any inconsistency between any such Schedules or Exhibits and this Agreement, the terms of this Agreement shall
govern.


 


26          English
Language


 


This Agreement is written and executed in the English
language. Any translation into any other language shall not be an official version of this Agreement and in the event of any conflict
in interpretation between the English version and such translation, the English version shall prevail.


 


27          Amendment


 


Any amendment or modification of this Agreement
must be in writing and signed by authorised representatives of both Parties.


 


28          Waiver
and Non-Exclusion of Remedies


 


A Party’s failure to enforce, at any time
or for any period of time, any provision of this Agreement, or to exercise any right or remedy shall not constitute a waiver of
that provision, right or remedy or prevent such Party from enforcing any or all provisions of this Agreement and exercising any
rights or remedies. To be effective any waiver must be in writing. All rights and remedies are cumulative and do not exclude any
other right or remedy provided by law or otherwise available.


 



    	 	Page 62 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


29          No
Benefit to Third Parties 


 


Except for any rights and immunities granted in
this Agreement to any AstraZeneca Affiliates, the Contracts (Rights of Third Parties) Act 1999 shall not apply to this Agreement.
Except as set forth in Article 19, no Person who is not a party to this Agreement (including any Affiliate, employee, officer,
agent, representative, Sublicensee or subcontractor of either Party) shall have the right (whether under the Contracts (Rights
of Third Parties) Act 1999 or otherwise) to enforce any term of this Agreement which expressly or by implication confers a benefit
on that Person without the express prior agreement in writing of the Parties, which agreement must refer to this Article 29.


 


30          Further
Assurance


 


Each Party shall perform all further acts and things
and execute and deliver such further documents as may be necessary or as the other Party may reasonably require to implement or
give effect to this Agreement.


 


31          Expenses


 


Except as otherwise expressly provided in this Agreement,
each Party shall pay the fees and expenses of its respective lawyers and all other expenses and costs incurred by such Party incidental
to the negotiation, preparation, execution and delivery of this Agreement.


 


32          Counterparts


 


This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original and all of which taken together shall be deemed to constitute one and the
same instrument. An executed signature page of this Agreement delivered by facsimile transmission or by electronic mail in “portable
document format” (“.pdf”) shall be as effective as an original executed signature page.


 


THIS AGREEMENT IS EXECUTED by the authorised representatives
of the Parties as of the date first written above.


 


	SIGNED for and on behalf of

AstraZeneca AB (publ)	 	SIGNED for and on behalf of

Neoprobe Corporation
	 	 	 
	Signature    /s/ Anders Buren	 	Signature    /s/  Brent L. Larson
	Name:	Anders Buren	 	Name:	Brent L. Larson
	Title:	Authorised Signatory	 	Title:	Sr. VP & CFO


 



    	 	Page 63 of 63	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


Schedule 1


 


AZD4694 Compound


 


[18F]AZD4694


 


Structural formula


 


 


 


	Molecular formula	C14H1118FN2O2
	 	 
	Relative molecular mass	M.W = 257.26 g/mol
	 	 
	Chirality/stereochemistry	N/A
	 	 
	Systematic chemical name (IUPAC)	2-(2-[18F]Fluoro-6-methylamino-pyridin-3-yl)-benzofuran-5-ol
	 	 
	(CAS) registry number	1211333-21-9


 



    	 	Page 1 of 1	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


Schedule 2


 


AZD4694 Global Development Plan


 


[*]


 



    	 	Page 1 of 1	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


Schedule 3


 


Licensed Know-How


 


	Preclinical	 
	 	 
	
        Medicinal chemistry

         

        [*]
	 
	 	 
	
        Pharmacokinetics

         

        [*]
	 
	 	 
	
        Pharmacology

         

        [*]
	 
	 	 
	
        Toxicology

        [*]
	 


 



    	 	Page 1 of 4	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


	Pharmaceutical Development
	 


[*]


 



    	 	Page 2 of 4	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


	Clinical
	 
	Approvals
	 
	[*]
	 
	Informed Consent Forms
	 
	[*]
	 
	Protocols
	 
	[*]
	 
	Report [*]
	 
	[*]
	 
	Case Report Form [*] Study [*]
	 
	[*]
	 
	Case Report Form [*] Study [*]
	 
	Case Report Form
	 
	Case Report Form Banner Study [*]
	 
	Case Report Form
	 


 



    	 	Page 3 of 4	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


	
Regulatory
	 
	Copy of all submission documents and correspondence in relation to Clinical Trial Application:

[*]
	 
	Copy of all submission documents and correspondence in relation to Clinical Trial Application:

[*]
	 
	Copy of all submission documents, correspondence and amendments to the [*]
	 
	[*]
	 
	[*]
	 
	[*]
	 
	[*]
	 
	
        Current version Clinical Summaries:

         

        [*]

	 
	
        Current version Nonclinical Summaries:

         

        [*]

	 
	Investigator's Brochure edition 1
	 
	Investigator's Brochure edition 2
	 


 



    	 	Page 4 of 4	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


Schedule 4


 


Licensed Patents


 


Family List – External


 


	Docket Number	[*]
	 	 
	Att.Attorney	[*]
	 	 
	Inventor(s)	[*]


 


	Title	[*]


 


Country     Sort
No.     Filing      Case
Type     Convention Type     Application
No     Application Dt     Patent
No     Grant Dt     Expiration
Dt     Status


[*]


 


25 October 2011         Page
1


 



    	 	Page 1 of 4	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


Family List – External


 


Country     Sort
No.     Filing      Case
Type     Convention Type     Application
No     Application Dt     Patent
No     Grant Dt     Expiration
Dt     Status


[*]


 


25 October 2011         Page
2


 






    	 	Page 2 of 4	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    
 


Family List – External


 


	Docket Number	[*]
	 	 
	Att.Attorney	[*]
	 	 
	Inventor(s)	[*]


 


	Title	[*]


 


Country     Sort
No.     Filing      Case
Type     Convention Type     Application
No     Application Dt     Patent
No     Grant Dt     Expiration
Dt     Status


[*]


 


25 October 2011         Page
1


 



    	 	Page 3 of 4	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


Family List – External


 


Country     Sort
No.      Filing      Case Type     Convention
Type     Application No     Application
Dt     Patent No     Grant
Dt     Expiration Dt     Status


[*]


 


25 October 2011         Page
2


 



    	 	Page 4 of 4	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


Schedule 5


 


Study Plans


 


List of AstraZeneca sponsored studies AZD4694


 


	Study	 	FSI	 	Study report
	 	 	 	 	 
	[*]	 	[*]	 	[*]
	 	 	 	 	 
	[*]	 	[*]	 	[*]
	 	 	 	 	 
	[*]	 	[*]	 	[*]


 


 


	Study	 	FSI	 	Study report
	 	 	 	 	 
	[*]	 	[*]	 	[*]
	 	 	 	 	 
	[*]	 	[*]	 	[*]


 



    	 	Page 1 of 1	9 December 2011
AZ./.Neoprobe



    	Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.



    

 


Schedule 6


 


ISS Studies


 


List of Investigator Sponsor Studies AZD4694


 


	Study	 	FSI	 	
        Study report

        Estimated

	 	 	 	 	 
	[*]	 	[*]	 	[*]
	 	 	 	 	 
	[*]	 	[*]	 	[*]


 



    	 	Page 1 of 1	9 December 2011
AZ./.Neoprobe



    	 



    

 


Exhibit 1


 


Short-Form Patent Licence Agreement


 


Date:


 


Parties:


 


(1)         ‘The
Licensor’: ____________ having its registered office at __________.


 


(2)         ‘The
Licensee’: ____________ having its registered office at __________.


 


Recitals:


 


By an Agreement (‘the Main Agreement’) dated _________________
and made between the Licensor and the Licensee the Licensor granted for the consideration therein contained to the Licensee a licence
under [UK Patent No ________________] [European Patent (UK) No ________________] (‘the Patent’).


 


Operative provisions:


 


1.           In
pursuance of the Main Agreement and for the consideration referred to in the Main Agreement the Licensor hereby confirms the grant
to the Licensee of the exclusive licence from the Effective Date for the term specified in the Main Agreement to manufacture, market,
sell and otherwise dispose of Licensed Products (as defined in the Main Agreement) for the life of the Patent and subject to the
provisions of the Main Agreement.


 


2.           Subject
as provided in the Main Agreement this Licence shall terminate without notice in the event of the termination for any reason of
the Main Agreement. [Drafting Note: This is not always the case. This provision may need to be modified depending on the
termination provisions in the Main Agreement.]


 



    	 	Page 1 of 2	9 December 2011
AZ./.Neoprobe



    	 



    

 


IN WITNESS of which this Agreement has been executed as a deed
and delivered the day and year first above written.


 


EXECUTED as a Deed by _________________ acting by:

[name of director] and:

[name of director/secretary]


 


EXECUTED as a Deed by _________________ acting by:

[name of director] and:

[name of director/secretary]


 



    	 	Page 2 of 2	9 December 2011
AZ./.Neoprobe



    	 



    

 


Exhibit 2


 


Press Release


 


Neoprobe
Licenses AstraZeneca Imaging Agent for Amyloid Detection to Aid Diagnosis of Alzheimer’s Disease 


 


Dublin, Ohio –December 12, 2011 – Neoprobe Corporation
(NYSE Amex: NEOP) today announced that it has in-licensed the worldwide exclusive rights from AstraZeneca to the late-stage radiopharmaceutical
imaging candidate, AZD4694, for aiding the diagnosis of Alzheimer’s disease (AD).


 


AZD4694 is a Fluorine-18 labeled precision radiopharmaceutical
candidate for use in the imaging and evaluation of patients with signs or symptoms of cognitive impairment such as AD. It binds
to Beta-amyloid deposits in the brain that can then be imaged in positron emission tomography (PET) scans. Amyloid plaque pathology
is a required feature of AD diagnosis and the presence of amyloid pathology is a supportive feature for diagnosis of probable AD.
Patients who are negative for amyloid pathology do not have AD.


 


Clinical studies in more than 70 patients suggest that AZD4694
has the ability to image patients quickly and safely with high sensitivity. Importantly, AZD4694 exhibits low background and white
matter uptake, thereby providing clear images of Beta-amyloid deposits. Neoprobe intends to initiate a Phase III clinical program
in early 2013, while simultaneously building the requisite safety and training database. Patents and patent applications filed
around the world related to AZD4694 are effective until 2028.


 


“To gain the recognition of AstraZeneca through a rigorous
licensing process and secure such a promising late-stage imaging asset is a strong endorsement of our development capability and
focus,” commented Neoprobe’s Executive Vice President and Chief Business Officer, Thomas Tulip, Ph.D. “We believe
AZD4694 has a compelling global commercial outlook and should beneficially facilitate development of more effective disease-modifying
therapies for Alzheimer ́s disease. This potentially powerful second-generation agent with apparent best-in-class properties
has demonstrated strong performance attributes. We believe AZD4694 imaging may be quite useful as an adjunct measure in the diagnosis
of this large, growing disease and may allow patients to seek earlier, and therefore potentially more effective, treatment options.”


 


“The discovery and development of new treatments for Alzheimer’s
disease is a top priority for AstraZeneca. This alliance couples Neoprobe’s expertise in diagnostic imaging with our own
expertise in the discovery and development of innovative medicines, and will further expand our ability to evaluate new treatments
for Alzheimer’s disease in the future,” said Christer Köhler, Vice President and Head of CNS & Pain Innovative
Medicines at AstraZeneca.


 



    	 	Page 1 of 3	9 December 2011
AZ./.Neoprobe



    	 



    

 


“New Alzheimer’s disease imaging agents are potentially
powerful tools in aiding the diagnosis of AD and evaluation of new drugs aiming to modify amyloid plaque levels and possibly alter
disease progression. Having worked in the development of first-generation agents, early data suggests that AZD4694 may have imaging
performance and convenience attributes making it a best-in-class prospect for accurate and earlier disease definition,” said
Dr. Kenneth Marek, Chief Executive Officer and Co-Founder of Molecular NeuroImaging (MNI). MNI is a world leader in neuroscience
and radiopharmaceutical imaging for the diagnosis and monitoring of neurological and neuropsychiatric disorders. MNI will be a
key collaborator with Neoprobe in the clinical development of AZD4694.


 


Financial terms of the in-licensing agreement include an upfront
payment of $5 million to AstraZeneca and a series of contingent milestone payments including up to $6.5 million in potential payments
based on the achievement of clinical development and regulatory filing milestones and up to additional $11 million due following
the receipt of regulatory approvals and the initiation of commercial sales. In addition, Neoprobe will pay AstraZeneca royalties
on net sales of the approved product. AstraZeneca retains the right to use AZD4694 in clinical trials to support development of
potential treatments for Alzheimer’s disease.


 


“Licensing this important asset is consistent with the
growth strategy to build out our precision radiopharmaceutical pipeline and transform Neoprobe into a leader in the development
and commercialization of targeted diagnostic agents,” stated Dr. Mark Pykett, Neoprobe’s President and CEO. “We
are encouraged to have secured a high-quality, late-stage asset from a world-class partner for a large and growing disease in a
patient community with significant unmet medical need. We are pleased to have structured an agreement for an asset that we believe
will return substantial value to our shareholders and where a significant part of the future compensation is based on the product’s
approval and ultimately product sales. We look forward to collaborating with AstraZeneca on the progress of this agent and assisting
them in the development of their Alzheimer’s disease therapeutics.”


 


Neoprobe’s President and CEO, Dr. Mark Pykett, Executive
Vice President and CBO, Dr. Thomas Tulip, and Senior Vice President and CFO, Brent Larson, will discuss the license transaction
during a conference call with the investment community scheduled for tomorrow morning, December 13, 2011 at 8:30 AM EST. The conference
call can be accessed as follows:


 


	Conference Call Information
	TO PARTICIPATE LIVE:	TO LISTEN TO A REPLAY:
	
        Date:

        Time:

         

        Toll-free (U.S.) Dial in # :

        International Dial in # :

         
	
        Dec. 13, 2011

        8:30 AM ET

         

        (877) 407-8033

        (201) 689-8016
	
        Available until:

        Toll-free (U.S.) Dial in # :

        International Dial in # :

         

        Replay passcode:

        Account #:

        Conference ID #:
	
        Dec. 27, 2011

        (877) 660-6853

        (201) 612-7415

         

         

        286

        384608

	 	 	 	 


 



    	 	Page 2 of 3	9 December 2011
AZ./.Neoprobe



    	 



    

 


About Alzheimer’s


Alzheimer’s
disease (AD) is a progressive and fatal neurodegenerative disease which affects a person’s memory and ability to learn,
reason, communicate and carry out daily activities. Increasing age is the greatest
risk factor for AD and there is no prevention or cure.  The World Health Organization
estimates that Alzheimer’s disease affects over 24,000,000 people worldwide. Currently
in the U.S. alone, there are over 5 million Alzheimer’s patients with estimates that by 2050, as many as 16 million Americans
could have the disease according to the Alzheimer’s Association. Among the brain changes believed to contribute
to the development of Alzheimer’s are the accumulation of the protein beta-amyloid outside nerve cells (neurons) in
the brain and the accumulation of the protein tau inside neurons. Approximately 75 to 100 experimental therapies aimed at
diagnosing, slowing or stopping the progression of Alzheimer’s are now in human clinical trials.


 


About AstraZeneca


AstraZeneca is a global, innovation-driven biopharmaceutical
business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal,
cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com


 


About Neoprobe


Neoprobe Corporation (NYSE Amex: NEOP) is a biopharmaceutical
company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Neoprobe is actively
developing three radiopharmaceutical agent platforms – Lymphoseek®, AZD4694 and RIGScanTM CR –
to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and
ultimately patient care. Neoprobe’s strategy is to deliver superior growth and shareholder return by bringing to market novel
radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization
efforts. For more information, please visit www.neoprobe.com.


 


The Private Securities Litigation Reform Act of 1995 (the
Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release,
which relate to other than strictly historical facts, such as statements about the Company’s plans and strategies, expectations
for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and
markets for the Company’s products are forward-looking statements within the meaning of the Act.  The words “believe,”
“expect,” “anticipate,” “estimate,” “project,” and similar expressions identify
forward-looking statements that speak only as of the date hereof.  Investors are cautioned that such statements involve risks
and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors
including, but not limited to, the Company’s continuing operating losses, uncertainty of market acceptance of its products,
reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on
limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development
of new products, regulatory risks and other risks detailed in the Company’s most recent Annual Report on Form 10-K and other
Securities and Exchange Commission filings.  The Company undertakes no obligation to publicly update or revise any forward-looking
statements.


 


Contact:


Neoprobe Corporation — Brent Larson, Sr. VP & CFO
– (614) 822-2330


 



    	 	Page 3 of 3	9 December 2011
AZ./.Neoprobe